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ABSTRACT 
 
Background Children with juvenile idiopathic arthritis (JIA) are predisposed 
to compromised bone health and alterations in body composition because of 
chronic inflammation, nutritional and hormonal disturbances, limited physical 
activity and glucocorticoid (GC) therapy. Compromised bone health may present 
as pathological vertebral compression fractures, but data on their prevalence 
and risk factors in children are limited. Excess fat, and especially adipose tissue-
derived adipokines leptin and adiponectin, may also contribute to impaired 
bone health. Furthermore, adipokines modulate immunity and inflammation 
in adults with rheumatic diseases, but their role in JIA has not been explored.
Objectives We evaluated bone health in patients with severe JIA and 
investigated body composition and adipokines and their contribution to bone 
health and disease activity in JIA.
Methods We recruited two cohorts of patients for cross-sectional studies. The 
severe JIA Cohort comprised 50 patients with severe polyarticular or systemic 
JIA. The GC-treated Cohort included 50 patients with JIA with mostly mild to 
moderate disease severity and at least three months' exposure to systemic 
GC. The results were compared with those of sex-and age-matched healthy 
controls. The study protocol included clinical and laboratory assessments, 
evaluation of bone mineral density (BMD) and body composition by dual-
energy X-ray absorptiometry (DXA), spinal radiography and spinal magnetic 
resonance imaging (MRI). 
Results Spinal radiography showed vertebral compression fractures in 22% of 
the patients with severe JIA. Patients with fractures had higher weight-adjusted 
cumulative GC dose, higher disease activity and higher body mass index than 
those without fractures. Bone age-corrected BMD Z-scores for lumbar spine and 
whole body were similar between those with and without fractures. On spinal 
MRI, altogether 28% of patients with severe JIA showed vertebral fractures 
and several other vertebral changes, including end plate irregularities in 26%, 
anterior vertebral corner lesions in 16% and disc changes in 46%. Based on 
concentrations of bone turnover markers, the patients with severe JIA had 
increased bone resorption, but normal bone formation. Further, patients with 
severe JIA had increased body adiposity, and their serum leptin was increased 
even independently of fat mass. Leptin showed an inverse association with 
bone turnover markers in patients, while in controls the association was 
dependent on fat mass. 
In the GC-treated Cohort, fat mass, lean mass and serum leptin and adiponectin 
were similar to those of controls, but patients had slightly lower BMD values 
than controls. Those patients with lumbar spine BMD Z-score <-1.0 tended to 
have higher serum leptin values than those with higher BMD Z-scores, but in 
8regression analysis leptin was not associated with BMD. Adipokines did not 
correlate with current disease activity in either patient cohort.
Conclusions Patients with severe JIA have compromised bone health based 
on high prevalence of compression fractures. Risk factors include high GC 
exposure, high disease activity and high body mass index. BMD, as measured by 
DXA, is unable to differentiate between those with and without compression 
fractures. According to spinal MRI findings, patients with severe JIA have, 
besides compression fractures, several other changes involving intervertebral 
discs and vertebral end plates; the clinical relevance of these remains uncertain. 
Patients with severe JIA are prone to high adiposity, whereas those with less 
severe disease have normal body composition despite previous GC exposure. 
Leptin may negatively contribute to bone metabolism in severe JIA, but larger 
and longitudinal studies are needed to prove causality and to evaluate whether 
these preliminary findings are generalizable to other JIA groups. We did not 
observe a correlation between leptin or adiponectin and disease activity in 
either JIA cohort. The possible role of adipokines as a modulator of immunity 
and inflammation in JIA remains to be evaluated. 
ABSTRACT
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Tausta Lastenreumaan eli juveniiliin idiopaattiseen artriittiin (JIA) voi liittyä ke-
hon koostumuksen muutoksia ja luuston terveyden heikentymistä. Näille altis-
tavia tekijöitä ovat krooninen tulehdustila, ravitsemukselliset ja hormonaaliset 
tekijät, luustoa kuormittavan liikunnan vähäisyys sekä glukokortikoidihoito. 
Kroonisia sairauksia kuten liikuntavammaisuutta, syöpäsairauksia tai autoim-
muunitauteja sairastavilla lapsilla voi esiintyä selkänikamien murtumia merkki-
nä patologisesta luuston hauraudesta. Lastenreumaa sairastavien nikamamur-
tumien esiintyvyydestä, riskitekijöistä ja diagnostiikasta on rajallisesti tutkittua 
tietoa. Myös lihavuus saattaa olla yksi luuston terveyteen haitallisesti vaikut-
tava riskitekijä. Rasvakudoksen ja luuston välisen vuorovaikutuksen mekanis-
meja tunnetaan vielä melko huonosti, mutta rasvakudoksen erittämien adi-
pokiinien, leptiinin ja adiponektiinin, on esitetty olevan osallisina. Adipokiinit 
myös muokkaavat immuunivastetta. Aikuisiän nivelreumassa korkea leptiini- ja 
adiponektiinipitoisuus ovat yhteydessä taudin aktiivisuuteen, mutta lastenreu-
maa sairastavilla yhteyttä ei ole tutkittu.   
Tutkimuksen tarkoitus Tutkimuksen tarkoituksena oli selvittää nikamamur-
tumien ja muiden selkärangan poikkeavuuksien esiintyvyyttä ja riskitekijöitä 
vaikeaa lastenreumaa sairastavilla potilailla. Lisäksi tutkittiin lastenreumaa sai-
rastavien lasten ja nuorten kehon koostumusta, adipokiinien pitoisuuksia ja 
adipokiinien yhteyttä luuston aineenvaihduntaan, luun mineraalitiheyteen ja 
taudin aktiivisuuteen. 
Menetelmät Poikkileikkaustutkimukseen rekrytoitiin kaksi potilaskohorttia. 
Toisessa kohortissa oli 50 vaikeaa lastenreumaa sairastavaa lasta ja nuorta. 
Toisessa kohortissa oli 50 lastenreumapotilasta, jotka olivat saaneet systeemistä 
glukokortikoidihoitoa vähintään 3 kuukauden ajan, mutta joiden lastenreuma 
oli luonteeltaan keskimäärin lievempi. Adipokiinien, luustomarkkereiden ja 
luun mineraalitiheyden välistä vuorovaikutusta selvittäneissä tutkimuksissa tu-
loksia verrattiin iän ja sukupuolen suhteen kaltaistettujen terveiden verrokei-
den tuloksiin. Tutkittaville tehtiin kliininen tutkimus, laboratoriotutkimuksia ja 
luuston mineraalitiheyden mittaus. Vaikeaa lastenreumaa sairastaville potilail-
le tehtiin lisäksi selkärangan röntgenkuvaus ja magneettikuvaus. 
Tulokset Tulokset osoittivat, että selän nikamamurtumat ja muut poikkeavuu-
det ovat yleisiä vaikeaa lastenreumaa sairastavilla. Heistä 22%:lla todettiin 
nikamamurtumia selän röntgenkuvissa. Kolmen edeltävän vuoden kumulatii-
vinen painoon suhteutettu kortisoniannos, taudin aktiivisuus ja painoindeksi 
olivat suuremmat nikamamurtumia saaneilla verrattuna niihin, joilla murtumia 
ei todettu. Luuston mineraalitiheys ei kuitenkaan eronnut näiden ryhmien vä-
lillä. Selkärangan magneettikuvauksessa nikamamurtumia oli 28%:lla ja lisäksi 
havaittiin runsaasti muita muutoksia: päätelevyn epätasaisuuksia (26%), nika-
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man etunurkan muutoksia (16%) sekä välilevymuutoksia (46%). Niillä joilla ku-
vantamismuutoksia todettiin, oli taipumus olla muita lihavampia. Vaikeaa las-
tenreumaa sairastavilla luuston hajoamista kuvaavan merkkiaineen pitoisuus 
oli korkeampi kuin verrokeilla, mutta luuston muodostusmarkkereiden pitoi-
suudet eivät eronneet ryhmien välillä. Vaikeaa lastenreumaa sairastavat olivat 
selvästi lihavampia kuin verrokit. Heillä todettiin korkeampi seerumin leptiini-
pitoisuus sekä käänteinen yhteys leptiinin ja luustomarkkereiden välillä myös 
silloin, kun rasvan määrä sekoittavana tekijänä otettiin huomioon. Verrokeilla 
vastaava yhteys näytti olevan rasvakudoksesta riippuvainen.
Glukokortikoidihoitoa saaneiden mutta lievempää lastenreumaa sairastavien 
lasten kohortissa kehon koostumus tai seerumin leptiini- ja adiponektiinipi-
toisuudet eivät eronneet verrokeista. Potilailla oli kuitenkin lievästi alentu-
nut luun mineraalitiheys. Potilailla, joilla lannerangan luuntiheys oli ≤-1.0 SD, 
oli taipumus suurempaan leptiinipitoisuuteen kuin niillä joiden luuntiheys 
oli >-1.0 SD. Leptiini ei kuitenkaan ollut yhteydessä luun mineraalitiheyteen 
monimuuttuja-analyysissä. Leptiini ja adiponektiini eivät korreloineet taudin 
aktiivisuuteen kummassakaan lastenreumaa sairastavien kohortissa. 
Johtopäätökset Nikamamurtumat ovat yleisiä vaikeaa lastenreumaa sairas-
tavilla lapsilla ja nuorilla. Altistavia tekijöitä ovat korkea kolmen edeltävän 
vuoden kumulatiivinen kortisoniannos, taudin aktiivisuus ja lihavuus. Luuston 
mineraalitiheysmittaus ei kykene erottelemaan nikamamurtumia saaneita 
muista potilaista. Selkärangan magneettikuvaus löytää enemmän murtumia, 
mutta myös runsaasti muita muutoksia. Vaikea lastenreuma altistaa lihavuu-
delle, mutta lievempää tautia sairastavien kehon koostumus ei eroa terveistä 
ikätovereista. Altistuminen pieniannoksiselle kortisonihoidolle ei näytä vaikut-
tavan haitallisesti kehon koostumukseen. Leptiinillä saattaa olla negatiivinen 
vaikutus luuston aineenvaihduntaan vaikeassa lastenreumassa. Tutkimuksessa 
ei todettu yhteyttä leptiinin tai adiponektiinin ja taudin aktiivisuuden välillä. 
LYHENNELMÄ
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ALP Alkaline phosphatase
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CT Computed tomography
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1. INTRODUCTION  
While non-vertebral fractures are common in childhood, vertebral fractures 
are rare in healthy children and adolescents and, when present, suggest 
compromised bone health (Mäkitie 2013). According to clinical experience and 
published reports, vertebral compression fractures appear in certain chronic 
diseases, including juvenile idiopathic arthritis (JIA). Compression fractures 
may remain undetected, as they appear even in individuals with normal bone 
mineral density and are often asymptomatic, especially in children. Impaired 
bone health in JIA may arise from several disease- and treatment-related 
factors such as inflammatory cytokines, nutritional and hormonal disturbances, 
limited physical activity and glucocorticoid (GC) therapy (Burnham 2012).
Because of these risk factors, JIA may also be associated with altered body 
composition (Bechtold 2009). Inflammatory cytokines, GCs and limited physical 
activity cause muscle wasting, leading to impaired bone mass accrual. Patients 
suffering from malnutrition are likely to have decreased fat mass, while GC 
therapy and limited physical activity predispose to excessive fat mass. Increasing 
childhood obesity is a worldwide epidemic that also affects patients with JIA 
(Han et al. 2010). Both low and high fat mass may be associated with adverse 
skeletal effects (Viljakainen 2011). Recent data suggest that despite increased 
mechanical loading obesity may be an additional risk factor for impaired bone 
mass accrual and increased fracture risk in childhood (Dimitri et al. 2012). 
The underlying mechanisms are largely unknown, but adipose tissue-derived 
biochemical factors, called adipokines, have been suggested to play a role. 
Adipokines also modulate immune responses.   
Data are limited on the prevalence, risk factors and diagnostics of vertebral 
compression fractures in JIA. Very little is known about the fat-bone relationship 
in healthy children, and especially in chronic diseases, including JIA. Our aim, 
therefore, was to evaluate the prevalence, risk factors and diagnostics of 
compression fractures in severe JIA. Secondly, we examined body composition 
and the relationship of adipokines with serum bone turnover markers, bone 
mineral density and disease activity in JIA. 
INTRODUCTION
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2. REVIEW OF THE LITERATURE
2.1 Juvenile idiopathic arthritis
2.1.1 Definition and epidemiology
Juvenile idiopathic arthritis (JIA) applies to any arthritis of unknown origin that 
lasts for more than 6 weeks and begins before the age of 16 years (Petty and 
Cassidy 2011). For diagnosis, exclusion of other diseases known to cause arthritis 
is required. JIA is not a single disease entity, but is a group of heterogeneous 
disease states. In order to characterize homogeneous disease groups, several 
classification criteria have been published. To standardize the classification, 
internationally acknowledged criteria for JIA have been proposed since 1993 
by the International League of Associations for Rheumatology (ILAR). The 
current classification (Petty et al. 2004) and the estimated proportion of JIA 
subtypes are presented in Table 1 (Ravelli and Martini 2007). 
TABLE 1. Frequency of disease subtypes according to the ILAR classification for 
juvenile i diopathic arthritis (JIA).
JIA subtype Frequency
Systemic arthritis 4-17%
Oligoarthritis; persistent or extended 27-56%
Rheumatoid factor-positive polyarthritis 2-7%
Rheumatoid factor-negative polyarthritis 11-28%
Enthesitis-related arthritis 3-11%
Psoriatic arthritis 2-11%
Undifferentiated arthritis 11-21%
The reported prevalence and incidence of JIA vary considerably throughout the 
world (Ravelli and Martini 2007). This may reflect diverse classification criteria and 
heterogeneity of the disease as well as differences in ethnicity, immunogenicity 
and environmental factors. However, most studies have been conducted on 
Caucasians in Europe or North America and only a few in developing countries. 
Data from developed countries indicate a yearly prevalence of 16-150/100 000. 
Community-based studies on schoolchildren from Belgium and Australia report 
the highest prevalence, up to 167-400/100 000, implying that chronic arthritis 
may remain undiagnosed in a substantial proportion of children (Mielants 
et al. 1993, Manners and Diepeveen 1996). A longitudinal multicentre study 
estimates an average JIA incidence of about 15/100 000 in Nordic countries 
and about 21/100 000 in the Helsinki area in Finland (Berntson et al. 2003). 
A Canadian epidemiologic study of a multi-ethnic cohort shows that JIA is 
over-represented in children of European origin, who are at the highest risk 
of developing any of the JIA subtypes, except for rheumatoid factor-positive 
REVIEW OF THE LITERATURE
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polyarthritis, and are especially susceptible to extended oligoarthritis and 
psoriatic arthritis (Saurenmann et al. 2007). Oligoarthritis is the most common 
subtype also in the Nordic countries (Nordal et al. 2011). Other autoimmune 
diseases, such as celiac disease or type I diabetes, are over-represented in 
patients with JIA and their relatives (Pohjankoski et al.  2012).
2.1.2 Aetiology and pathogenesis 
The aetiology and pathogenesis of JIA are poorly understood, but seem to be 
multifactorial, including both genetic and environmental factors (Prakken et al. 
2011). Local tissue damage due to environmental factors, such as viral infections or 
vaccinations, are assumed to serve as a trigger for an adaptive response towards a 
self-antigen in a genetically susceptible individual. Once the autoimmune process is 
ongoing, a range of innate and adaptive immune responses is activated. Synovial 
inflammation follows as a consequence of an imbalance between proinflammatory 
effector cells (such as T-helper-17 cells) and anti-inflammatory regulatory cells 
(such as FOXP3-positive regulatory T cells). The hyperplastic vascularized synovium 
is infiltrated by several cell types, including T cells, B cells, macrophages, dendritic 
cells and plasma cells. The inflammatory process may lead to pannus formation, 
referring to destructive synovial tissue growth towards the cartilage and eventually 
to erosions of cartilage and bone.  Many susceptibility genes have been identified, 
involving both human leucocyte antigen (HLA) genes and non-HLA-related genes 
(Ravelli and Martini 2007). Genetic similarity with rheumatoid arthritis (RA) exists 
only regarding rheumatoid factor-positive polyarthritis, which is associated with 
HLA-DR4.  The genetic and immunological profile of systemic arthritis is clearly 
different from the other subtypes, characterized by a pronounced activation of the 
innate immune system and the absence of an association with autoantigens and HLA; 
systemic arthritis is now characterized as a polygenic autoinflammatory syndrome 
(Prakken et al. 2011). The target of international collaboration and multinational 
studies is to characterize genetic and biological markers for better prediction of 
disease characteristics, prognosis and drug responsiveness, eventually aiming at 
more individualized therapies (Prakken et al. 2011, Schmeling et al. 2014).
2.1.3 Complications, comorbidities and prognosis
Patients with JIA are at risk for multiple complications arising from several 
disease- and treatment-related factors. These comorbidities include uveitis 
and associated complications, such as glaucoma and cataract, although visual 
impairment is nowadays rare (Kotaniemi et al. 2014). Further, JIA predisposes 
to overall and local disturbances of growth, pubertal delay, altered body 
composition, impaired bone mass accrual and increased risk for fractures 
as well as cardiovascular changes (Smith et al. 2013). More than half of the 
patients with JIA still have signs of active disease in young adulthood, despite 
one-fourth using biological drugs (Vidqvist et al. 2013).
REVIEW OF THE LITERATURE
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2.2 Body composition 
2.2.1 Definitions
Body composition comprises fat mass and fat-free mass (2-compartment model) 
(Wells et al. 1999). In the so-called 4-compartment model, the fat-free mass 
consists of water, protein and mineral. In the 3-compartment model, fat-free 
mass includes bone mineral and lean mass, indicating soft tissues other than 
fat, i.e. mostly muscle (Figure 1). Confusingly, fat-free mass is sometimes called 
lean body mass or lean mass; in this text, however, lean mass refers to soft tissue 
without bone mineral. Body composition is prone to constant changes in order 
to adapt to current requirements. These changes are regulated by multiple 
factors, including nutrition, physical activity, hormonal factors, immunity and 
inflammation (Veldhuis et al. 2005, Bechtold and Roth 2009). Especially during 
puberty, body composition changes considerably and shows sexual dimorphism. 
Girls gain considerable amounts of fat and less lean mass, while boys mostly 
gain lean mass (Wells 2007). 
FIGURE 1. Schematic representation of 2-, 3- and 4-compartment models of body 
composition. BMC, bone mineral content. 
2.2.2 Assessment of body composition
Anthropometric methods
Body composition can be estimated by several anthropometric methods, 
including skinfold measurements, arm muscle circumference or waist-to-hip 
ratio (Wells and Fewtrell 2006). Body mass index (BMI), weight divided by 
height squared (kg/m2), has a limited value when assessing body composition 
since BMI does not differentiate between fat mass and lean mass. Similar to 
	  
REVIEW OF THE LITERATURE
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BMI, indices for fat mass and fat-free mass relative to body weight have been 
developed (VanItallie et al. 1990). Fat mass index (FMI) is calculated as fat mass 
divided by height squared (kg/m2), fat-free mass index (FFMI) as fat-free mass 
divided by height squared and lean mass index (LMI) as lean mass divided by 
height squared. 
Dual-energy X-ray absorptiometry  
For more precise body composition analysis, indirect technical methods, such 
as bioelectrical impedance, have been suggested. The reference method 
for body composition analysis is the 4-compartment (4-C) model (Wells and 
Fewtrell 2006). It is, however, time-consuming and difficult to perform on 
young or sick children, as it requires fasting and includes several procedures, 
e.g. underwater weighing. Therefore, the easily available whole-body dual-
energy X-ray absorptiometry (DXA) scanning with low radiation dose is 
nowadays the most popular method for body composition analysis in children 
and adolescents. However, different methods may yield variable estimates of 
body composition. One study evaluated DXA (Lunar DPX/DPX-L) against the 4-C 
model in 411 healthy children and adolescents aged 6-18 years and showed a 
strong relationship between the two methods, although DXA underestimated 
fat percentage (fat%) in those with lower fat% and overestimated fat% 
in those with higher fat% (Sopher et al. 2004). The researchers concluded 
that despite its limitations DXA is suitable for body composition analysis in 
paediatric populations. As measurements vary between devices from different 
manufacturers, cross-calibration methods have been developed. Shepherd et al. 
(2012) published paediatric cross-calibration equations to enable comparison 
of results from the two most commonly used manufacturers, GE Healthcare 
Lunar and Hologic. 
2.2.3 Body composition in juvenile idiopathic arthritis 
Rheumatoid cachexia or rheumatoid cachectic obesity is a well-known 
complication of rheumatoid arthritis (Rall 2004). It manifests as low lean mass 
and increased fat mass accompanied by whole-body catabolism, even if BMI 
is normal. Studies specifically evaluating body composition in JIA are scarce, 
although children also are predisposed to alterations of body composition 
resulting from several factors (Figure 2). Inflammatory cytokines cause 
increased protein catabolism and poor appetite (Rall and Roubenoff 2004), 
which may also result from other factors such as gastrointestinal side-effects of 
medication, pain or depression. Patients with systemic arthritis have increased 
resting energy expenditure (Knops et al. 1999). A discrepancy between 
increased caloric needs and diminished intake may lead to protein/energy 
malnutrition. Physical inactivity and GCs may further exacerbate decrease in 
muscle mass (Roth et al. 2007, van Raalte et al. 2009). Several earlier studies 
have observed evidence of malnutrition based on low BMI Z-score, diminished 
anthropometric measurements such as arm muscle circumference, reduced 
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intakes of energy and protein or deficiencies in biochemical nutritional values 
(Johansson et al. 1986, Henderson and Lovell 1989, Lofthouse et al. 2002, 
Perfetto et al. 2005, Souza et al. 2006). Nutritional deficits seem to occur 
especially in patients with systemic or polyarticular JIA, but also those with 
persistent oligoarticular disease may be affected (Henderson and Lovell 1989, 
Cleary et al. 2004). By using a bioelectrical impedance method, Lofthouse and 
colleagues (2002) reported nutritional impairment in those with polyarticular 
disease, as evidenced by lower fat% and lower total body water, indicating 
lower lean mass, while those with oligoarthritis only show low body fat%. 
Contrary to these findings, some studies report normal (Henderson et al. 2000, 
Valta et al. 2007) or even high BMI in patients with JIA (Caetano et al. 2012, 
Pelajo et al. 2012). A very recent Finnish study with 40 prepubertal children with 
JIA and low disease activity showed increased energy intake and signs of higher 
central and peripheral adiposity, as evidenced by higher waist circumference and 
biceps skinfold thickness relative to healthy controls (Grönlund et al. 2014). The 
tendency for higher BMI may be at least partly related to the global epidemic 
of increasing obesity associated with sedentary lifestyle and physical inactivity. 
Further, GCs induce an increase and redistribution of body fat by accelerating 
fat accumulation in visceral adipose tissue and diminishing peripheral fat stores 
(van Raalte et al. 2009). However, Souza et al. (2006) report no association 
between cumulative GC dose and BMI.
 
In DXA studies, patients with paediatric rheumatic diseases and high-dose GC 
exposure have shown increased fat mass and diminished lean mass (Mul et al. 
2002). In a prospective study by Lien et al. (2005), patients with early JIA had 
lower gains of lean mass and higher gains of fat% than healthy controls during 
the 2-year follow-up, indicating that body composition may be altered already 
early in the disease. A recent peripheral quantitative computed tomography 
(pQCT) study on children and young adults with a mean disease duration of 
5.6 years showed less muscle and more fat in JIA patients than in controls, 
and these correlated with disease activity and systemic or intra-articular GCs 
(Stagi et al. 2014). On the other hand, young adults with JIA in remission after 
a median disease duration of 15.5 years have shown an even better nutritional 
status with less body fat and more lean mass than healthy controls (Haugen 
et al. 2002). Especially before the era of biological drugs, also those with GC 
treatment have shown low BMI. It is likely that severe disease course, physical 
impairment and malnutrition have earlier been more common than today, 
contributing to diminished fat mass and muscle mass. The possible effects of 
biological drugs on appetite or metabolism are largely unknown, but some 
adult studies suggest a tendency for weight gain (Briot et al. 2008, Engvall et 
al. 2010). Another important factor affecting body composition in JIA is the 
tendency for pubertal delay, which postpones gender-specific pubertal changes 
in body composition. Recombinant human growth hormone therapy has shown 
not only accelerated growth but also changes in body composition by inducing 
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an increase in lean mass and, to a lesser extent, a decrease in excessive fat mass 
(Bechtold and Simon 2014).   
FIGURE 2. Disease- and treatment-related factors with potential effects on body 
composition and bone health in JIA. BMI, body mass index; BMC, bone mineral 
content; BMD, bone mineral density. 
2.3 Bone 
2.3.1 Bone structure and function
The skeleton is part of the locomotor system and provides protection for inner 
organs and bone marrow (Baron 2003). It also forms a reservoir for storage 
of calcium, phosphorus and magnesium and participates in the regulation of 
mineral homeostasis. Bone acts as an endocrine organ by secreting hormones, 
including fibroblast growth factor 23 and osteocalcin, thereby regulating 
phosphate metabolism, energy homeostasis and male reproduction (Fukumoto 
and Martin 2009, Karsenty and Ferron 2012). The unmineralized organic bone 
matrix, the osteoid, consists mainly (90%) of type I collagen fibres, but includes 
also non-collagenous proteins, such as glycoproteins and proteoglycans, with 
bone cells comprising only 2% (Baron 2003). The bone matrix is mineralized by 
calcium and phosphate-containing hydroxyapatite crystals. This combination 
enables flexibility and stiffness, both important for resisting fractures. Cortical 
bone comprises about 85% of total bone and is mostly found in the shafts of 
long bones, while the metabolically active trabecular (cancellous) bone exists 
at the end of long bones, in vertebrae and near joint surfaces. The primary 
structural difference between these two types of bone is that 80-90% of the 
volume of cortical bone but only 15-25% of trabecular bone is calcified.
2.3.2 Bone cells
The bone-forming osteoblasts arise from mesenchymal stem cells that also 
give rise to chondrocytes, myocytes, fibroblasts and adipocytes (Baron 2003). 
Osteoblasts produce type I collagen and other components for the collagenous 
matrix, and the osteoid is subsequently mineralized. Osteocytes develop from 
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osteoblasts that have been entrapped in the mineralized matrix. Osteocytes 
participate in matrix maintenance and mineral homeostasis and communicate 
with osteoblasts and osteoclast precursors via cytoplasmic processes. Those 
osteoblasts that stop bone formation turn into bone lining cells that remain on 
the bone surface. Bone-resorbing osteoclasts are large multinuclear cells that 
originate from a haematopoietic stem cell similar to macrophages. Osteoclasts 
resorb bone by releasing acid and proteolytic enzymes to break down the 
organic matrix. 
2.3.3 Bone growth, modelling and remodelling 
Longitudinal bone growth is driven by a process called endochondral 
ossification, which adds cartilage tissue to the growth plates situated at 
the ends of long bones, then transforming into bone tissue at the adjacent 
metaphyses (Schoenau et al. 2004, Rauch 2006). Bone growth in both width 
and shape during childhood occurs by a process called modelling, where 
osteoblasts and osteoclasts function independently of each other on opposite 
sides of a piece of bone. Osteoblasts deposit and mineralize bone matrix on 
the periosteal (outer) surface, thereby increasing the outer circumference of 
bone (periosteal apposition), while osteoclasts resorb bone on the endocortical 
(inner) surface of bone, increasing the size of the marrow cavity. Since more 
bone is formed than resorbed, the net effect of modelling usually leads to 
thickening of the cortex. Bone remodelling takes place in basic multicellular 
units and consists of successive cycles of bone resorption, followed by repair 
due to new bone formation on the same bone surface. “Coupling” refers to 
the activation of bone forming osteoblasts being tightly linked to the previous 
action by osteoclasts. The bone resorption cycle lasts about 10 days, followed 
by bone formation evolving over three months (Singer and Eyre 2008). The 
main outcome of bone remodelling, in addition to maintenance of calcium 
homeostasis, is to renew bone. Since the remodelling balance is usually near 
zero, the process has little effect on the amount of bone (Schoenau et al. 2004). 
Most bone turnover takes place in trabecular bone due to its high surface area 
relative to that of cortical bone. Bone remodelling and modelling processes are 
presented in Figure 3.
In prepuberty, longitudinal bone growth occurs mainly in the lower limbs, 
while spinal growth predominates in puberty. Almost half of adult peak bone 
mass, achieved in the third decade, is accrued during the 3-4 years following 
onset of puberty (Bailey 1997). Bone mass tends to show “tracking”, indicating 
that low bone mass during early childhood predicts low peak bone mass (Wren 
et al. 2011). Several environmental factors designate whether the genetically 
determined peak bone mass can be achieved (Arikoski et al. 2002). Due to 
earlier onset of puberty, girls reach their peak height velocity earlier than boys, 
at approximately 12 and 14 years in girls and boys, respectively. Obese children 
reach their peak height velocity earlier than lean children (Marcovecchio and 
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Chiarelli 2013). Bones grow longer and wider in boys due to an increase in 
muscle mass and a prolonged period of periosteal apposition.  
FIGURE 3. Bone remodelling and modelling. Bone repair by remodelling designates 
a tightly coupled process of bone formation by osteoblasts to form the osteoid 
for subsequent mineralization, followed by resorption by osteoclasts. Bone 
turnover markers comprise tissue proteins, their fragments or enzymes, which are 
released during remodelling and can be measured in blood or urine. Osteocytes 
act as mechanosensors and communicate via cytoplasmic processes to regulate 
the balance between bone formation and resorption. In modelling, osteoblasts 
function on the periosteal and osteoclasts on the endosteal bone surface to enable 
bone growth in width and shape. 
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2.3.4 Regulators of bone 
Hormonal factors  
Hormonal, mechanical and local signals influence bone remodelling. The main 
hormones regulating plasma calcium and phosphate concentrations include 
parathyroid hormone (PTH) and vitamin D in its active form, 1,25-dihydroxy 
vitamin D (1,25(OH)2D ) (Misra et al. 2008). Hypocalcaemia due to inadequate 
dietary intake or intestinal absorption of calcium triggers PTH excretion, 
resulting in increased bone resorption, enhanced renal calcium reabsorption 
from the distal tubulus and increased renal synthesis of 1,25(OH)2D. Vitamin 
D can be acquired through two different routes. By ultraviolet radiation, 
7-dehydrocholesterol in the skin is converted to vitamin D3 and then transported 
to the liver by vitamin D binding protein. Because UV exposure may be limited 
due to northern or southern latitudes, clothing, etc., intestinal absorption from 
vitamin D-containing food either as vitamin D2 or D3 is of importance. Via hepatic 
25-hydroxylase, vitamin D is converted to 25-hydroxyvitamin D (25-OHD), which 
is the main circulating vitamin D metabolite and reflects body vitamin D status. 
Further hydroxylation of 25-OHD to 1,25(OH)2D is accomplished by kidney 
1α-hydroxylase (also expressed in several extrarenal tissues), which is activated 
by low serum calcium or phosphate or by elevated PTH levels. Because of tight 
feedback regulative mechanisms, synthesis of 1,25(OH)2D declines when serum 
calcium and phosphate are normal. To remove excess vitamin D, another renal 
enzyme 24-hydroxylase is activated due to high serum calcium or phosphate 
and conversion of 25-OHD to 24,25-dihydroxyvitamin D follows (Figure 4).
Several other hormones also regulate bone growth and mineralization (Välimäki 
and Mäkitie 2009). Growth hormone acts mainly through insulin-like growth 
factor 1 (IGF-1) on osteoblast function and is the main regulator of bone growth 
before puberty (Giustina et al. 2008). In addition, the effects of sex steroids are 
important for bone growth during puberty and for maintenance of bone mass 
in adulthood (Wells 2007). Oestrogen contributes to endocortical apposition 
in girls, and through aromatization of testosterone to oestradiol also in boys, 
whereas testosterone increases muscle mass and periosteal apposition and 
thereby bone cross-sectional size and strength in boys. Also thyroid hormones, 
insulin, enteric hormones, cortisol, calcitonin, fibroblast growth factor 23 and 
adipokines have modifying effects on bone metabolism (Fukumoto and Martin 
2009, Misra and Klibanski 2013, Mäkitie 2013, Wojcicka et al. 2013).
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FIGURE 4. Metabolism and effects of vitamin D. Sources of vitamin D include 
vitamin D-containing food, such as oily fish or fortified margarine or milk 
products, and production in skin via UV-B radiation. Vitamin D is transported to 
the liver by vitamin D binding protein (DBP), and converted to 25-hydroxyvitamin 
D (25-OHD), which reflects body vitamin D status. Further hydroxylation of 25-
OHD to 1,25(OH)2D is accomplished by kidney 1α-hydroxylase (also expressed in 
extrarenal tissues), which is activated by low serum calcium (Ca) or phosphate 
(Pi) or elevated parathyroid hormone (PTH), growth hormone (GH) or oestrogen 
levels. Because of tight feedback regulative mechanisms, synthesis of 1,25(OH)2D 
declines when serum calcium and phosphate are normal. To remove excess vitamin 
D, renal 24-hydroxylase is activated due to high serum calcium or phosphate, and 
conversion of 25-OHD to 24,25-dihydroxyvitamin D follows. Vitamin D regulates 
calcium homeostasis and skeletal health. Vitamin D is also important for muscle 
health, and several extraskeletal effects have been suggested.
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Local factors 
A multitude of local hormones, growth factors, cytokines and other factors 
regulate the differentiation and proliferation of osteoblast and osteoclast 
lineage cells. The reciprocal relationship between osteoblasts and osteoclasts 
plays a key role (Schett 2010a). The most important local regulatory pathway 
of osteoclastic bone resorption is the RANKL/RANK/OPG pathway (Figure 5). 
Macrophage colony-stimulating factor (M-CSF) is another important factor 
upregulating osteoclasts. The differentiation of osteoblasts is dependent 
on, for example,  transcription factors. Further, one key regulator in 
osteoblastogenesis is the wingless-type (WNT) signalling pathway, consisting of 
molecules that are important regulators of bone formation (Baron 2013). WNT 
signalling also suppresses osteoclast formation by modulating the production 
of osteoprotegerin (OPG). 
  
FIGURE 5. Regulation of osteoclasts by the RANKL/RANK/OPG pathway. Osteoblasts 
express receptor activator of nuclear factor kappa-B ligand (RANKL), a member of 
the tumour necrosis factor (TNF) superfamily, which can be cleaved to activate 
osteoclastogenesis by activating its receptor RANK on osteoclasts. At the same 
time, osteoblasts secrete osteoprotegerin (OPG), a RANKL decoy receptor capable 
of inhibiting osteoclast formation. The RANKL/RANK/OPG system is regulated by 
multiple factors.
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Mechanical factors  
Bone is a dynamic tissue that is able to change its mass and structure by 
responding to mechanical forces. The “mechanostat” theory described by 
Frost (1987) reflects the intrinsic control of bone in adapting to mechanical 
forces by altering its structural characteristics, necessitating bone formation 
or resorption at any given moment. The mechanosensory role of osteocytes 
in orchestrating these processes and in maintaining bone quality seems to 
be crucial (Bonewald 2011). The relationship between muscle and bone is 
emphasized by the “functional muscle-bone unit” model, which determines 
whether deficits of bone, muscle or both are the reason for bone loss, indicating 
a primary, secondary or mixed bone disorder, respectively (Schoenau et al. 
2002). Studies on unilateral or generalized physical loading show a significant 
positive effect on bone mass and structure (Kannus et al. 1995, Baxter-Jones et 
al. 2008, Nikander et al. 2010). 
Genetics  
Twin studies suggest that about 80% of the variance in BMD is determined 
by genetic factors (Pocock et al. 1987). Genetic factors are also important 
in the regulation of bone size, geometric properties and bone remodelling 
activity. Regulation of these osteoporosis-related phenotypes is polygenic, 
and each gene shows rather small effects (Ralston 2010). Rare severe forms 
of osteoporosis are monogenic and result from a mutation in a single gene 
(Mäkitie 2013). The most common form of primary osteoporosis is osteogenesis 
imperfecta, which in types I-IV is caused by a defect in type I collagen resulting 
from mutations in COL1A1 and COL1A2 genes, but also several other genetic 
defects in osteogenesis imperfecta types V-XIII have been recognized. Another 
example of primary osteoporosis relates to mutations in the low-density 
lipoprotein receptor-related protein (LRP5) gene, which encodes a co-receptor 
for the WNT signalling pathway and is thus important for osteoblast function. 
Biallelic loss-of-function mutations in LRP5 cause a disorder called osteoporosis-
pseudoglioma syndrome. However, even heterozygotes for LRP5 mutations 
have low bone mass, and several polymorphisms in LRP5 and LRP6 genes 
are associated with bone mass accrual and fractures. Similarly biallelic and 
heterozygous mutations in the gene encoding WNT1, a major ligand for the 
WNT signalling pathway, result in osteoporosis phenotypes of variable severity 
(Laine et al. 2013). 
2.3.5 Deficiency of calcium and vitamin D  
Deficient calcium or phosphate intake results in decreased osteoid 
mineralization, leading to osteomalacia in adults and rickets in children, as 
mineral deficiency affects the organization and mineralization of cartilaginous 
growth plates before epiphyseal fusion. Sufficient calcium intake is especially 
important during the pubertal growth spurt to enable maximal bone mass 
accrual, but excess calcium seems not to have much effect on bone mass 
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accrual in healthy children (Winzenberg et al. 2006). Rickets continues to be 
a significant problem in Western countries, especially among immigrants with 
dark skin pigmentation (Shaw and Mughal 2013). Although controversy exists 
about adequate vitamin D status, recent studies suggest that despite vitamin 
D-fortified foods and guidelines for supplement use vitamin D insufficiency 
(25-OHD <50 nmol/l) and deficiency (<37.5 nmol/l) are common throughout 
the world. In Finland, up to 70% of 7- to 19-year-olds are vitamin D insufficient 
in spite of median vitamin D intakes of 9-10 ug/day (Pekkinen et al. 2012). 
Furthermore, low serum 25-OHD concentrations are associated with low BMD, 
and 25-OHD values explain almost 10% of the variation in lumbar spine or 
whole-body BMD, even surpassing the effects of physical activity. Finnish data 
from 2007 to 2010 show that altogether 47% of children with chronic diseases, 
and especially adolescents, have insufficient serum 25-OHD concentration 
(Holmlund-Suila et al. 2013). Intrauterine and early postnatal vitamin D status 
seems to be important for later bone mass accrual. Neonates born to mothers 
with low vitamin D levels show decreased tibial BMC and smaller cross-sectional 
area in pQCT (Viljakainen et al. 2010). Further, according to data from the UK, 
low maternal 25-OHD is associated with lower whole-body and lumbar spine 
BMC of the child at the age of 9 (Javaid et al. 2006). Not all postnatal vitamin 
D supplementation studies show positive results on bone mass accrual, but 
the pre- and peripubertal period may be an especially favourable period to 
attain positive effects from supplementation (Viljakainen et al. 2006). In 2014, 
the Finnish Nutrition Council increased the recommended total daily vitamin 
D intake from 7.5 to 10 ug and suggested daily supplementation of 7.5 ug 
throughout the year for children aged 2-18 years and 10 µg for those under the 
age of 2 (National Nutrition Council 2014).
Extraskeletal effects of vitamin D
Several observational studies suggest positive extraskeletal effects of vitamin 
D (Hossein-Nezhad and Holick 2013). Vitamin D deficiency is associated with an 
increased risk of developing several diseases, including certain malignancies, 
infectious diseases, asthma, metabolic syndrome, cardiovascular diseases and 
cognitive impairment. There is evidence of immunomodulatory effects. Vitamin 
D supplementation during early life may reduce the risk for type 1 diabetes, 
and a relationship between vitamin D and other autoimmune diseases, such as 
multiple sclerosis, Crohn’s disease and RA, has also been suggested. Deficiency 
of vitamin D is also associated with a more active disease course. Children with 
JIA, especially those with polyarticular or systemic disease, may have a tendency 
for low levels of vitamin D, but it is unclear whether supplementation has an 
effect on disease outcome (Nisar et al. 2013). Since results from intervention 
studies are inconsistent, further evidence is needed to confirm the promising 
role of vitamin D in extraskeletal health of adults and children (Hossein-Nezhad 
and Holick 2013, Saggese et al. 2015) (Figure 4).
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2.3.6 Fracture incidence and associated factors in childhood 
Fractures are common in children; about 50% of boys and 30-40% of girls 
sustain at least one fracture during childhood (Landin 1983, Jones et al. 2002). 
Fracture incidence is highest during mid-puberty (Landin 1983, Mäyränpää et al. 
2010), which may at least partially result from a decrease in the ratio of cortical 
to trabecular bone simultaneously with a peak in cortical porosity (Kirmani 
et al. 2009). Both increase (Landin 1997, Mäyränpää et al. 2010) and, more 
recently, decrease of overall fracture incidence during childhood have been 
reported in Sweden and Finland (Tiderius 1999, Mäyränpää et al. 2010). The 
fracture pattern has changed during recent decades since despite a decrease 
in hand and foot fractures an increase in clinically more significant forearm 
fractures has been reported in many studies (Khosla et al. 2003, Helenius et al. 
2009, Mäyränpää et al. 2010). Several predisposing factors for the first fracture 
as well as for subsequent fractures in fracture-prone children have been 
recognized (Goulding et al. 2000 and 2005, Manias et al. 2006, Mäyränpää et 
al. 2012). These include low intakes of milk, calcium and vitamin D, low serum 
25-OHD, maternal smoking during pregnancy and absence of breast-feeding, 
higher consumption of carbonated beverages, early age at first fracture and 
history of fractures in siblings, low levels of physical activity, low BMC or BMD, 
and higher BMI. In a population-based cohort of almost 1400 children aged 
0-15 years, the prevalence of thoraco-lumbar vertebral fractures accounted 
for only 1% of all acute fractures (Mäyränpää et al. 2010). However, up to 
15% of 55 fracture-prone children with a history of at least two to three long 
bone fractures showed asymptomatic vertebral compression changes on spinal 
assessment (Mäyränpää et al. 2012). 
2.3.7 Osteoporosis and definitions for skeletal fragility in childhood 
According to WHO, osteoporosis has been defined as a skeletal disorder 
characterized by low bone mass and micro-architectural deterioration of 
bone tissue with a consequent increase in bone fragility and susceptibility to 
fracture (Kanis 1994). Another definition published by the National Institute 
of Health (NIH) described osteoporosis as a skeletal disorder characterized 
by compromised bone strength and increased risk of fracture (NIH 2001). In 
adults, according to WHO recommendations, osteoporosis can be diagnosed 
based on a DXA-derived BMD T-score of less than or equal to -2.5. To calculate 
a T-score, bone densitometry data are compared with results of 20- to 30-year-
old healthy persons, i.e. those with peak bone mass. These recommendations 
are based on epidemiological studies of osteoporotic fracture risk (Kanis 1994). 
This definition seems limited, however, since about 50% of all non-vertebral 
fractures occur at a T-score above -2.5 (Schuit et al. 2004). 
In children and adolescents, age- and sex-specific BMD reference data are 
used to calculate a Z-score, designating the magnitude of standard deviation 
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from the population mean. Low BMD alone is not sufficient for diagnosing 
osteoporosis in children because no BMD cut-off value predictive of increased 
fracture risk is known. According to the 2007 International Society for Clinical 
Densitometry (ISCD) Pediatric Official Positions, the diagnosis of osteoporosis in 
children requires both low bone mineral content (BMC) or areal bone mineral 
density (aBMD) (≤ -2.0) and a significant history of fractures (Rauch et al. 2008). 
These fractures may include either one vertebral fracture or one lower limb 
long bone fracture or two upper limb long bone fractures. BMC or aBMD results 
should be adjusted for age, gender and body size, as appropriate. The recent 
revised ISCD 2013 recommendation (Bishop et al. 2014) includes the following 
modifications:  a) In addition to vertebral fracture, a clinically significant fracture 
history means either two or more long bone fractures by age 10 years or three 
or more long bone fractures at any age before 16 years, excluding high-energy 
trauma (fall from > 3 m or traffic accidents) and b) A vertebral compression 
fracture alone (crush; loss of vertebral height at any part of >20%), regardless 
of BMD, is indicative of osteoporosis in the absence of local disease or high-
energy trauma. It was also stated that a BMC/aBMD Z-score >-2.0 does not 
preclude the possibility of skeletal fragility and increased fracture risk. In the 
absence of a significant fracture history, the terms osteoporosis and osteopenia 
in a paediatric setting should be avoided and the terms “low BMD for body 
size” for Z-score ≤-2.0 and “low-normal BMD for body size” for Z-score >-2.0- 
-1.0 preferred (Bianchi et al. 2014). 
Primary osteoporosis in otherwise healthy childen is rare, while secondary 
osteoporosis is common, especially in children with diseases involving chronic 
systemic inflammation, neuromuscular disabilities, GC treatment or cancer 
therapies, including chemotherapy and radiotherapy (Kröger and Arikoski 
2004, Mäkitie 2013). Signs of compromised bone health may be observed not 
only after treatment but already at disease onset of childhood malignancies 
(Arikoski et al. 1999a,b).
 
2.4 Assessment of bone health
2.4.1 Dual-energy X-ray absorptiometry
  
DXA measures the relative tissue absorption of X-rays at high and low energies. 
DXA measurement provides the projectional bone area, bone mineral content 
and areal bone density as g/cm2. The interpretation of DXA results is not simple 
in children, and certain pitfalls have been recognized (Gafni and Baron 2004). 
The most significant limitation of DXA is the analysis of a three-dimensional 
object with a two-dimensional projection (Crabtree et al. 2014). Because 
DXA is not able to measure bone depth, results are dependent on bone size. 
Therefore, DXA underestimates bone density of a short child with smaller bones 
and overestimates bone density of a tall child with bigger bones. Algorithms 
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for counting true volumetric BMD have been developed. Based on current 
recommendations, DXA results should be corrected for body size. However, 
these suggestions are based on data from healthy children, and correction for 
bone age may be appropriate in children with chronic disease, considering 
delay in skeletal maturation. Another limitation of DXA is that it is unable to 
distinguish between cortical and trabecular bone, but measurements of the 
whole body and lumbar spine serve as surrogates for cortical and trabecular 
bone health, respectively. 
2.4.2 Biochemistry  
Measurements of serum or urine calcium and phosphorus are surrogates for body 
calcium balance, but do not reflect skeletal reserves of these minerals. Calcium 
balance is regulated by hormonal factors, such as parathyroid hormone, and the 
biologically active vitamin D metabolite 1,25-(OH)2D, but body vitamin D status 
can be estimated by measuring serum 25-OHD concentration (Misra et al. 2008). 
Bone turnover markers
The biochemical markers of bone turnover measured from blood or urine 
reflect the activity of osteoclasts and osteoblasts, but since formation and 
resorption are usually tightly coupled in time and space, any of the markers 
reflects the overall rate of bone turnover (Singer and Eyre 2008). In adults, 
bone turnover markers mainly represent remodelling, while in children these 
markers are released also during modelling and skeletal longitudinal growth. 
Bone turnover can be more than 10 times greater in children than in adults, 
and turnover markers increase especially during the pubertal growth spurt 
while declining in late puberty (Rauchenzauner et al. 2007). Interpretation of 
bone turnover marker values is complicated because of several confounding 
factors, especially in children. In addition to age, pubertal stage and growth 
velocity, these include hormonal factors, nutritional status, circadian and day-
to-day variation and methodological issues (Szulc et al. 2000, Paldanius et al. 
2012, Viljakainen et al. 2014). 
Turnover markers are bone tissue proteins or their fragments or enxymes released 
from bone cells during bone turnover (Singer and Eyre 2008) (Figure 3). Several 
formation markers are available. Alkaline phosphatase (S-ALP) is an enzyme 
found on the osteoblast cell surface that is thought to play a role in osteoid 
formation and mineralization, thereby reflecting osteoblast activity. Osteocalcin 
(S-OC) is a protein of the bone matrix with a high affinity to hydroxyapatite. 
Osteocalcin is considered a specific marker of osteoblast activity and bone 
formation, but it may be released also during bone resorption, which is reflected 
by urinary osteocalcin. Procollagen type I amino-terminal and carboxy-terminal 
propeptides (PINP and PICP) are quantitative measures of newly formed type I 
collagen. The most used resorption markers include crosslinked telopeptides of 
type I collagen in their amino-terminal (NTX) and carboxy-terminal (CTX and 
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ICTP) forms. NTX and CTX are released by cathepsin K cleavage, whereas ICTP 
is a larger fragment degraded by matrix metalloproteinases. Tartrate-resistant 
acid phosphatase 5b (S-TRACP5b) is a catalytic enzyme that reflects the number 
of osteoclasts rather than their activity.  
2.4.3 Spinal imaging
Assessment of vertebral morphology by radiography  
The classification by Genant et al. (1993) is the most commonly used method 
for vertebral fracture assessment in adults. Since the Genant method is based 
on adult data, Mäkitie et al. (2005) have proposed another classification 
method developed especially for the paediatric population. According to 
the Mäkitie method, compression fractures are classified as anterior wedge 
deformities (only anterior part of the vertebra compressed) or compression 
deformities (also the middle and/or posterior part of the vertebra compressed). 
Abnormal changes are further classified as mild (Grade 2a) or severe (Grade 
2b) wedge deformities or mild (Grade 3a) or severe (Grade 3b) compression 
deformities. Grades 1a-c represent normal variants of vertebral morphology 
in children. Figure 6 presents the vertebral morphology assessment by the 
Mäkitie method. 
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FIGURE 6. Vertebral morphology assessment by the Mäkitie method (Mäkitie et 
al. 2005). Figures used with the permission of copyright holder. Grades 0 and 
1a-c: Normal variants; Grades 2a and 2b: Progressive stages of anterior wedge 
deformity; Grades 3a and 3b: Progressive stages of compression deformity.  
A. In Grade 2a-2b wedge deformities, the intravertebral anterior height reduction 
(Z=Y-K/2) is >20%; ≥50% anterior height reduction in 2b (severe wedging). On 
intervertebral assessment, vertebral height reduction (Z-Lx100%) is 5-20% in 
Grade 2a and >20% in Grade 2b.
B. In compression deformities 3a and 3b, anterior, middle and posterior vertebral 
heights are reduced. On intravertebral assessment, the loss of middle height 
compared with posterior height (Z/Yx100%) is >20%. On intervertebral assessment, 
the middle vertebral height reduction compared with an apparently normal 
adjacent vertebra (Z/Lx100%) is 5-30% in Grade 3a and >30% in Grade 3b (severe 
deformity).
Spinal radiographs remain the golden standard for vertebral fracture 
assessment, but due to suboptimal visibility of the vertebrae, especially in the 
thoracic area, other methods such as computed tomography (CT) or magnetic 
resonance imaging (MRI) have been suggested. CT is commonly used in adults 
for thoracolumbar trauma imaging, but in order to avoid radiation exposure, 
the use of CT in children is limited. 
Magnetic resonance imaging  
Magnetic resonance imaging (MRI) is based on detecting signals from protons 
in the tissue hydrogen atoms within a strong magnetic field produced by 
the MRI scanner (Soimakallio et al. 2005). Hydrogen atoms are excited by a 
radiofrequency energy pulse to emit a radiofrequency signal, which can be 
measured. The contrast between different tissues is determined by proton 
density and the rate at which excited atoms return to the state of equilibrium. 
Differing magnetization relaxation processes produce tissue-specific values. T1-
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weighted images are used especially to visualize anatomical structures, while 
T2-weighted images can show pathology such as abnormal tissue oedema. 
Contrast agents such as gadolinium enhance sensitivity and specificity of 
MRI scans and are used to visualize inflammatory lesions. MRI is increasingly 
being used in children because it lacks ionizing radiation. In spinal imaging, 
MRI is superior to conventional radiography in visualization of vertebral 
changes, including subchondral bone and endplates, and in depiction of 
soft tissue (Sledge et al. 2001). MRI is the most sensitive imaging modality 
to detect inflammatory lesions of the axial skeleton, found in adult patients 
with ankylosing spondylitis (Pedersen et al. 2012). In JIA, MRI is increasingly 
used for imaging of affected joints, but challenges remain resulting from 
limited normative data of growth-related changes in healthy children (Lanni 
et al. 2014). Apart from the cervical spine and sacroiliac joints, involvement 
of the axial skeleton in JIA remains inadequately studied. Disadvantages of 
MRI include limited availability, long scanning time, need for sedation in small 
children and high cost. Contraindications involve metallic implants and cardiac 
pacemakers. 
2.4.4 Other imaging methods and bone histomorphometry 
Fracture is related to decreased bone strength, which does not depend only 
on BMD but also on bone quality (Griffith et al. 2010). Bone quality refers 
to such factors as bone architecture, turnover, mineralization and cellularity. 
New high-resolution imaging techniques, such as DXA-based hip structural 
analysis, pQCT, high-resolution pQCT and MRI, enable more precise evaluation 
of bone architecture and strength. Histomorphometric analysis of transiliac 
bone biopsy gives information on bone metabolism, mass and structure (of 
mainly trabecular bone) and is indicated in children with severe bone fragility 
of unknown origin (Rauch 2006).
 
2.5 Bone health in juvenile idiopathic arthritis 
2.5.1 Effect of chronic inflammation on bone  
Bone is a reservoir for haematopoietic stem cells, from which all immune cells 
are generated (Schett 2010a). Therefore, bone homeostasis is likely to regulate 
immune responses and immune memory. Further, osteoclasts originate from the 
monocyte-macrophage lineage and are actually specialized macrophages with 
bone-resorbing properties. The relationship between bone and the immune 
system is bidirectional since immune cells regulate bone remodelling (Schett 
2010a,b). These cells are capable of producing both pro-osteoclastogenic 
and anti-osteoclastogenic cytokines depending on the local environment. In 
rheumatic diseases, activation of the innate and adaptive immune system leads 
to the production of molecules with negative effects on bone homeostasis. 
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Enhancement of osteoclast function plays a key role, and the disturbed 
balance between bone formation and bone resorption eventually triggers 
bone loss. Macrophages, T cells and fibroblasts produce several inflammatory 
mediators, such as TNF, interleukin (IL) 1, IL-6, IL-17 and prostaglandin E2, 
which stimulate osteoclast formation and activation by inducing expression 
of RANKL and macrophage colony-stimulating factor (MCSF). Compensatory 
bone formation is blunted because of the inflammatory process. In fact, TNF 
downregulates bone formation firstly by inducing WNT antagonist Dickkoph 
1, and secondly by inducing the expression of the osteocyte product sclerostin, 
which is a suppressor of bone formation. As a consequence of these processes, 
periarticular and generalized osteoporosis follow. (Figure 7)
FIGURE 7. Influence of inflammation on bone remodelling. Several inflammatory 
mediators produced by macrophages, T cells or fibroblasts stimulate osteoclasts 
and bone resorption by inducing the expression of receptor activator of nuclear 
factor KB ligand (RANKL) and macrophage colony-stimulating factor (MCSF). Bone 
formation is downregulated by TNF by inducing a WNT antagonist Dickkopf and 
by inducing the expression of the osteocyte product Sclerostin, a suppressor of 
bone formation. Modified from Schett et al. (2010b)
2.5.2 Other disease-related factors  
Several other disease-related factors predispose children with JIA to impaired 
bone health. Deficits in muscle mass and function, resulting from effects of 
inflammatory cytokines, GCs and limited physical activity, are suggested to play 
a major role (Burnham et al. 2006b and 2008, Roth et al. 2007). Patients with 
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JIA have been shown to have low body fat content (Lofthouse et al. 2002), 
but also obesity (Caetano et al. 2012, Pelajo et al. 2012, Grönlund et al. 2014), 
both of which may predispose to low BMD (Veldhuis et al. 2005, Viljakainen 
et al. 2011, Misra and Klibanski 2013). In healthy children, pubertal delay is a 
risk factor for low peak bone mass (Gilsanz 2011). This concept is important in 
children with JIA, who often have pubertal delay. (Figure 2)
2.5.3 Glucocorticoids 
 
GCs have deleterious effects on bone, mainly trabecular bone. Children using 
GCs have increased fracture risk (Van Staa 2003). Bone resorption transiently 
increases, resulting from increased osteoclast survival (Canalis et al. 2007). 
Decreased bone formation also ensues because of increased apoptosis of 
mature osteoblasts and osteocytes during long-term GC therapy. Indirect GC 
effects include decreased intestinal calcium absorption, increased urinary 
calcium excretion (inducing hyperparathyroidism) and decreased synthesis of 
gonadotropins, sex steroids and IGF-1. Also myopathy associated with GCs can 
contribute to bone loss. 
2.5.4 Growth 
 
Impaired growth is a well-known complication of JIA (Bechtold 2014), resulting 
from effects of proinflammatory cytokines, malnutrition and GCs on the 
growth hormone-IGF-1 axis (Bechtold and Simon 2014). In addition to these 
systemic effects, inflammatory cytokines such as TNF-α, IL-1ß and IL-6 induce 
a direct effect on chondrogenesis in the growth plate. Recent advances in 
antirheumatic medication seem to have changed the growth pattern since 
normal growth has been reported despite previous GC exposure (Valta et al. 
2007). Anti-TNF-α modulators have been a treatment option for severe JIA since 
the late 1990s and have shown a positive impact on growth, although growth 
retardation still affects a subgroup of children (Tynjälä et al. 2006, Billiau et al. 
2010, Giannini et al. 2010). Catch-up growth is seen also with anti-IL-6 receptor 
antibody tocilizumab therapy in patients with systemic arthritis (de Benedetti 
et al. 2014). Positive results have been reported regarding growth hormone 
therapy in short children with JIA, but close monitoring is required because of 
increased risk for impaired glucose tolerance due to chronic inflammation and 
GC therapy (Bechtold and Simon 2014). Disease activity suppresses the effect of 
growth hormone on growth (Pepmueller et al. 1996).
2.5.5 Bone mineral density  
Several DXA studies report decreased BMC or BMD values in patients with JIA, 
either with or without GC exposure (Kotaniemi et al. 1993 and 1999, Pepmueller 
et al. 1996, Henderson et al. 1997 and 2000, Lien et al. 2003 and 2005, Valta 
et al. 2007, Stagi et al. 2014). Patients with systemic or polyarticular disease 
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are especially vulnerable to reductions in BMD.  A pQCT study by Burnham et 
al. (2008) showed deficits in periosteal circumference, muscle cross-sectional 
area and cortical section modulus (a measure of bending and torsional bone 
strength) and low trabecular volumetric BMD in all subtypes, excluding 
oligoarthritis. The authors concluded that patients with JIA seem to have a 
mixed bone deficit, indicating that bone mass is low even when considering 
the reduction in muscle mass. Complementary results were reported in a 
longitudinal study (Stagi et al. 2014). Some young adults with JIA in remission 
attain the same BMD as healthy subjects, but those with active disease are at 
greatest risk for osteoporosis (Zak et al. 1999, Haugen et al. 2000).
2.5.6 Fractures  
According to data from a large United Kingdom General Practice Research 
Database, subjects with childhood-onset arthritis have an increased risk for 
first fracture compared with healthy controls (Burnham et al. 2006a). The risk 
is highest during adolescence and after the age of 45 years. A prior fracture 
increases the risk for a new fracture by 86% in both patients and controls. 
No threshold for safe GC dosing is known since fractures appear even with 
relatively low dosages. Although children commonly sustain fractures, vertebral 
fractures are rare in healthy children and suggest skeletal fragility. Earlier 
cross-sectional studies report vertebral fractures in children with rheumatic 
diseases, especially in systemic lupus erythematosus (SLE) and other connective 
tissue diseases, vasculitis or systemic arthritis, and mostly in association with 
prolonged GC exposure (Badley and Ansell 1960, Elsasser et al. 1982, Varonos 
et al.  1987, Mäkitie et al. 2005, Valta et al. 2007, Nakhla et al. 2009). Other risk 
factors include prolonged bed rest, high disease activity, low BMD, subnormal 
vitamin D status and male sex. 
Huber et al. (2010) observed vertebral fractures in 7% of 134 children with 
various paediatric rheumatic conditions shortly after diagnosis, at only 30 days 
after initiation of GC therapy. Those with vertebral fractures included patients 
with juvenile dermatomyositis, systemic lupus erythematosus, systemic vasculitis 
and systemic arthritis (2 patients, 9%), but no patients with other JIA subtypes 
(n=28). In a 3-year prospective follow-up since GC initiation (n=110 at final 
visit), the incidence of vertebral fractures was 12.4%, and annual incidences in 
the first, second and third years were 6%, 4.8% and 3.6%, respectively (LeBlanc 
et al. 2015). During the first year of follow-up those with incident vertebral 
fractures had received about 50% more GCs (median daily dose 23 vs. 43 mg/
m2) than those without and showed more weight gain and greater decline in 
LS aBMD primarily during the first 6 months, but were mostly asymptomatic, 
similar to several other reports (Rodd et al. 2012). Every 0.5 mg/kg increase 
in average daily GC dose was associated with a 2-fold increased fracture risk, 
which was highest shortly after starting GC therapy and attenuated after 
cessation of treatment. However, two patients showed fractures more than 
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one year after cessation of GCs (LeBlanc et al. 2015). A Finnish study on 62 
children with JIA and at least 3-months’ systemic GC exposure prior to the 
study showed abnormal findings in 10% of the patients on vertebral fracture 
assessment based on DXA images, but these changes were not associated with 
cumulative GC dose, BMD, growth parameters or disease activity (Valta et al. 
2007). Also other studies have failed to demonstrate an association between 
vertebral fractures and lumbar BMD (Mäkitie et al. 2005, Nakhla et al. 2009). 
2.5.7 Bone turnover markers 
Previous JIA studies evaluating bone turnover markers mostly report reduced 
bone formation with or without an association with active disease (Pepmueller 
et al. 1996, Pereira et al. 1999, Lien et al. 2005). Results on bone resorption 
markers have been conflicting. 
 
2.6 Adipose tissue
2.6.1 Structure and function
Adipose tissue serves as an energy store, but recent research has expanded the 
understanding of the role of adipose tissue as the largest endocrine organ of 
the human body. Human adipose tissue comprises two general subtypes, white 
and brown adipose tissue. Recently, a third adipocyte type has been recognized, 
called brite (“brown-in-white”) or beige adipocyte (Lanthier and Leclercq 2014). 
Brown adipocytes oxidize fatty acids for thermogenesis and are present mainly 
in infants, although brown adipose tissue increases also during adolescence 
(Gilsanz et al. 2012). Beige adipocytes are localized inside white adipose tissue, 
have thermogenic properties and have a reversible tendency to transform into 
white adipocytes (Lanthier and Leclercq 2014). White adipocytes store energy 
as triglycerides. Although the majority of white adipose tissue mass consists 
of mature adipocytes, they account for less than 20% of the total cells. The 
other cells include pre-adipocytes, endothelial cells, fibroblasts, macrophages, 
lymphocytes and stem cells. White adipose tissue is divided into visceral and 
subcutaneous fat depots. Visceral obesity is also referred to as central or intra-
abdominal “apple-type” obesity, while subcutaneous fat excess localizes more 
peripherally. Positive caloric balance triggers mature adipocyte hypertrophy 
(increased cell size), and subsequently, adipogenesis, i.e. the differentiation of 
pre-adipocytes into new adipocytes.
Low-grade inflammation and metabolic syndrome  
Instead of controlled apoptosis, hypertrophic obesity is associated with 
necrotic cell death, which induces recruitment of macrophages and is followed 
by an inflammatory response (Lanthier and Leclercq 2014). Adipocytes and 
macrophages secrete various mediators, and this response is characterized 
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by high serum IL-6, TNF-α and CRP, and low adiponectin levels. The obesity-
associated low-grade inflammation is especially important concerning visceral 
adipose tissue; increased visceral fat is associated with a higher risk for metabolic 
syndrome than excess subcutaneous fat. Youth obesity is a significant risk factor 
for metabolic syndrome if obesity continues into adulthood (Mattsson et al. 
2008, Juonala et al. 2011).  
2.6.2 Adipokines 
Adipokines are small pleiotropic messenger proteins secreted mostly but not 
exclusively from adipose tissue (Tilg and Moschen 2006). These proteins function 
either as hormones to influence energy homeostasis and regulate neuroendocrine 
function or as cytokines to affect immune functions and inflammatory processes. 
Adipokines are widely involved in human physiology, participating in the regulation 
of appetite, energy expenditure, insulin sensitivity, coagulation, inflammation and 
bone homeostasis. A multitude of adipokines have been detected. The first to be 
discovered and the most studied are leptin and adiponectin. 
Leptin  
Leptin, a product of ob (obese) gene, was the first adipokine discovered in 1994 
(Zhang et al. 1994).  Leptin is a protein produced mainly by adipocytes, but also 
by the intestine, placenta, mammary glands, gastric epithelium, skeletal muscle 
and brain, and even by joint tissues and bone (Scotece et al. 2014). Leptin centrally 
regulates body weight by inducing reduced food intake and increased energy 
expenditure. In mouse models, leptin deficiency is associated with morbid obesity. 
Serum leptin levels are proportional to the overall fat tissue mass, but are 2-3 
times higher in females than in males even when adjusted for age and BMI (Tilg 
and Moschen 2006). In rats, leptin administration induces a reduction of visceral 
fat, but in humans obese individuals fail to respond to leptin’s anorexigenic effects 
because of hypothalamic leptin resistance (Scotece et al. 2014). However, it is 
unknown whether these obesity-related central mechanisms similarly regulate 
leptin’s peripheral actions. The effects of leptin are primarily proinflammatory. 
Adiponectin  
Adiponectin was discovered in 1995-1996 by several groups. Adiponectin is 
produced mainly by adipocytes, but under certain circumstances also by other 
cells such as skeletal and cardiac myocytes, endothelial cells, hepatocytes and 
osteoblasts (Tilg and Moschen 2006). Adiponectin exists as a full-length protein 
(either as low-, middle- or high-molecular weight forms) and as a globular 
fragment, and circulates in human serum at significantly higher concentrations 
than leptin. Adiponectin shows mostly anti-inflammatory effects by suppressing 
the synthesis of proinflammatory cytokines such as TNF-α and by producing 
anti-inflammatory cytokines such as IL-10 or IL-1 receptor antagonist. It also 
suppresses the monocyte-macrophage system. Adiponectin prevents insulin 
resistance by stimulating glucose uptake and fatty acid oxidation and is 
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protective against atherosclerosis. Decreased serum adiponectin values 
are associated with (visceral) obesity, insulin resistance and atherosclerosis. 
Conversely, in certain situations, including rheumatic diseases, adiponectin also 
has proinflammatory effects (Gomez et al. 2011).
2.7 Interaction between adipose tissue and bone 
2.7.1 Fat and bone
There is growing interest in the relationship between fat and bone, beginning 
with the fact that adipocytes and osteoblasts both originate from mesenchymal 
stem cells (Figure 8), and differentiation into the adipocyte or osteoblast 
lineage has a potential influence on skeletal homeostasis (Misra and Klibanski 
2013). Thus far, controversy remains whether fat is beneficial or harmful to 
bone from childhood into adulthood (Dimitri et al. 2012). Body weight is an 
important determinant of BMD. Studies on adults show a positive correlation 
between BMI or fat mass and DXA-derived BMD (Reid et al. 1992). BMI was 
protective against total fractures, osteoporotic fractures and hip fractures 
in a meta-analysis comprising 60 000 men and women (De Laet et al. 2005). 
In contrast, a retrospective study on 1005 postmenopausal women younger 
than 75 years reported a 28% prevalence of obesity in those with low-trauma 
fractures, despite mostly normal BMD (Premaor et al. 2010). 
FIGURE 8. Origin of and crosstalk between adipocytes, bone cells and macrophages. 
Adipocytes and osteoblasts originate from mesenchymal stem cells, whereas 
osteoclasts and macrophages originate from the haematopoietic stem cell lineage. 
Adipocytes and macrophages secrete cytokines that affect the RANKL/RANK/OPG 
pathway, thereby inducing bone resorption. Adipokines regulate bone remodelling 
in several ways. 
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The relationship between fat and bone is even more complex during childhood 
and adolescence, as changes in body composition and bone during growth 
and especially during puberty complicate the interpretation. Low fat mass is 
associated with detrimental hormonal changes and low BMD (van Raalte et al. 
2009, Viljakainen et al. 2011, Misra and Klibanski 2013). Although some of the 
obesity-associated hormonal changes, such as high insulin, levels are potentially 
anabolic for bone, cross-sectional studies suggest that high fat mass may also 
have a negative impact on bone during childhood and adolescence (Dimitri et al. 
2010, Viljakainen et al. 2011, Misra and Klibanski 2013). Obese children appear 
to have more fractures than their lean peers (Goulding 2005 et al., Manias et 
al. 2006), and high fat mass was associated with increased risk of subsequent 
fractures during a 4-year follow-up (Goulding et al. 2000, Jones et al. 2002). This 
may be partly explained by obesity-associated abnormalities in gait and balance, 
and subsequently, increased risk for falls (Goulding et al. 2003). However, despite 
having larger bone area (i.e. bigger bones) and compensatorily increased lean 
mass, obese children have low bone mass for their body size (Goulding et al. 
2000, Dimitri et al. 2010). This effect is emphasized in those with prior fractures 
(Dimitri et al. 2010). Obesity is also associated with poor bone quality and 
impaired mechanical properties (Farr et al. 2011). 
Nevertheless, the relationship between fat and bone may be age-specific. In 
prepubertal children aged 5-9 years, DXA studies show a positive relationship 
of fat mass with bone mass and size (Clark et al. 2006, Goulding et al. 2008, 
Cole et al. 2012), but this relationship is attenuated during puberty, at least in 
girls, and becomes negative immediately after puberty (Nagasaki 2004, Clark 
et al. 2006, Janicka et al. 2007). A pQCT study on 6-year-olds, however, reports 
an inverse association between fat mass and cortical and trabecular volumetric 
BMD already in prepubertal children (Cole et al. 2012). Regional fat distribution 
may be of importance since visceral and subcutaneous fat depots appear to 
have opposite effects. In females aged 15 to 25 years assessed by computed 
tomography, subcutaneous fat showed a beneficial effect on bone structure and 
strength in the femoral midshaft, while the impact of visceral fat was negative 
(Gilsanz et al. 2009). Consistent findings were observed in DXA assessment of 
obese adolescent girls (Russell et al. 2010). Furthermore, differences may exist 
between ethnic groups; the extent of a negative relationship with bone mass 
may be related more to subcutaneous fat in Caucasian and Latino children, and 
to visceral fat in Afro-Americans (Afghani and Goran 2006, 2009). 
The effect of childhood overweight on bone metabolism seems controversial 
since either normal or decreased bone formation (Bini et al. 2004, Reinehr and 
Roth 2010, Dimitri et al. 2011, Flemming et al. 2012,), and either unchanged, 
decreased or increased bone resorption markers (Bini et al. 2004, Dimitri et 
al. 2011, Viljakainen et al. 2011) in overweight or obese children have been 
reported. While most data are not based on longitudinal studies, it is largely 
unknown whether certain key stages exist when excess fat is detrimental 
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to bone mass accrual. Furthermore, the mechanisms responsible for these 
relationships are poorly understood; fat-derived proinflammatory cytokines 
and adipokines have been suggested to play a role (Figure 8). 
2.7.2 Leptin and bone
 
Most, but not all, in vitro studies report a direct positive effect of leptin on 
osteoblasts, while leptin also inhibits differentiation of bone marrow cells in 
the adipogenic direction (Scotece et al. 2014). Many in vivo studies on rodents 
show opposite results by suggesting an indirect negative effect of leptin on 
BMD through suppression of the serotonin system in the brain stem, thereby 
enhancing sympathetic output to the bone. Suppression of bone formation and 
increase of resorption follows (Ducy et al. 2000, Elefteriou et al. 2005). However, 
leptin also shows anabolic effects locally in the bone microenvironment 
(Burguera et al. 2001, Turner et al. 2013). A recent study on obese mice suggested 
differing effects of leptin on trabecular and cortical bone compartments, as 
leptin correlated negatively with trabecular BMD and positively with cortical 
bone cross-sectional area (Fujita et al. 2012). Clinical studies on adults have 
found either a positive or no association between serum leptin and BMD (Biver 
et al. 2011), but results from paediatric studies have been even more discordant. 
Healthy normal-weight (Roemmich 2003, Hong et al. 2010) or obese (Afghani 
and Goran 2009, Russell et al. 2010) children and adolescents show either a 
positive (Russell et al. 2010), a negative (Afghani and Goran 2009, Hong et 
al. 2010) or no relationship (Roemmich et al. 2003) between serum leptin and 
BMC or BMD. Inconsistent results have been published also regarding effects of 
leptin on bone turnover markers in children. Leptin has been associated either 
positively, negatively or not at all with markers of bone formation (Bini et al. 
2004, Reinehr and Roth  2010, Dimitri et al. 2011, Flemming 2012, VIljakainen 
et al. 2014) or bone resorption (Bini et al. 2004, Dimitri et al. 2011, Viljakainen 
et al. 2014). Weight loss is associated with increased formation markers, but not 
with ICTP (Bini et al. 2004). In conclusion, the role of leptin in bone metabolism 
remains poorly understood. 
2.7.3 Adiponectin and bone 
Adiponectin and its receptors are expressed in osteoblasts and osteoclasts 
(Shinoda et al. 2006). The in vitro effect of adiponectin on osteoclasts suggests 
either inhibition (Oshima et al. 2005) or indirect activation through stimulating 
RANKL and inhibiting OPG (Luo et al. 2006). Adiponectin stimulates the 
proliferation of osteoblasts in vitro (Luo et al. 2005), but may either increase 
(Oshima et al. 2005, Shinoda et al. 2006) or decrease bone mass in mice (Williams 
2009). Adiponectin affects bone formation by several routes, including 
local effects, via circulation or indirectly by, for instance, insulin signalling 
(Shinoda et al. 2006, Williams et al. 2009). Kajimura et al. (2013) suggest that 
adiponectin regulates bone mass in mice through opposite local and central 
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mechanisms. Local adiponectin downregulates osteoblast proliferation and 
favours osteoblast apoptosis, thereby reducing bone formation, bone mass 
and circulating osteocalcin levels. Conversely, adiponectin signals in the brain, 
inhibiting the activity of the sympathetic nervous system, and thus, increasing 
bone formation and bone mass. Suppression of the sympathetic tonus opposes 
the effects of leptin and leads also to a decrease in energy expenditure 
(Kajimura et al. 2013). However, clinical studies on adults show an inverse or 
absent relationship between serum adiponectin and BMD (Biver et al. 2011), 
and similar results have been reported in children (Hong et al. 2010, Russell et 
al. 2010, Sayers et al. 2010). In healthy lean or obese children, the scarce data 
show no correlations between adiponectin and bone turnover markers [Dimitri 
et al. 2011, Flemming et al. 2012]. 
2.8 Interaction of adipose tissue with immunity and 
inflammatory responses in rheumatic diseases 
Adipose tissue not only affects bone health but may also contribute to immunity 
and inflammatory responses in rheumatic diseases. Patients with low BMI have 
shown the highest scores for radiological damage, and high BMI has been 
proposed to be protective against these changes in RA (van der Helm-van Mill 
et al. 2008). Recent studies, by contrast, suggest a link between obesity and 
increased risk for RA (Crowson et al. 2013), and a positive association between 
obesity and disease activity (Ajeganova et al. 2013). Obesity also predicts poor 
response to treatment in early disease (Sandberg et al. 2014). Adipokines are 
speculated to play a causative role. 
2.8.1 Leptin and rheumatic diseases 
 
Conflicting data have emerged regarding whether leptin is harmful or 
protective for joint structures in RA. Most, but not all, recent data on patients 
with RA report increased serum leptin levels, which seem to correlate with 
CRP and higher disease activity. (Otero et al. 2006, Popa et al. 2009, Rho et al. 
2009, Gomez 2011, Olama et al. 2011, Yoshino et al. 2011). Leptin stimulates 
IL-6 production in synovial fibroblasts of RA patients (Muraoka et al. 2013). 
One study reported that RA patients have higher synovial fluid leptin levels 
than healthy controls with traumatic knee effusion and that the synovial fluid 
leptin-to-serum leptin ratio correlates with disease duration, more active 
disease and erosions (Olama et al. 2012). However, a protective effect of leptin 
against radiographic joint damage has also been described (Rho et al. 2009). 
Leptin modulates both innate and adaptive immunity. It activates monocytes 
and macrophages and regulates actions of natural killer cells and neutrophils. 
Concerning adaptive immunity, leptin promotes Th1 and downregulates Th2 
cell immune responses. It also suppresses the activity of regulatory T cells that 
act as regulators of autoimmunity (Notley and Ehrenstein 2010). 
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2.8.2 Adiponectin and rheumatic diseases 
Several studies report increased serum adiponectin levels in patients with RA 
(Otero et al. 2006, Popa et al. 2009, Rho et al. 2009, Yoshino et al. 2011). Serum 
adiponectin correlates inconsistently with disease activity and CRP (Otero et al. 
2006, Popa et al. 2009, Rho et al. 2009, Yoshino et al. 2011), but is associated 
with progression of radiological joint destruction (Ebina et al. 2009, Klein-
Wieringa et al. 2011, Meyer et al. 2013), and lean patients with low levels 
of visceral fat show the highest adiponectin levels and radiographic damage 
(Giles et al. 2009). These findings have been suggested to explain the protective 
effect of obesity against radiological progression (Gomez et al. 2011). Several 
findings suggest a proinflammatory role of adiponectin in the joint (Scotece 
et al. 2014). Adiponectin promotes chemotaxis and induces production of 
inflammatory cytokines, such as IL-6 and IL-8, possibly synergistically with IL-1ß. 
It may contribute to joint destruction by stimulating matrix metalloproteinases 
and vascular endothelial growth factor expression in the synovium. Moreover, 
adiponectin isoforms are able to induce the expression of different genes 
involved in the pathogenesis of RA. 
2.9 Role of fat/adipokines in juvenile idiopathic arthritis
2.9.1 Relationship between adipose tissue and bone in juvenile 
idiopathic arthritis  
Data regarding the relationship between fat mass or adipokines and bone 
metabolism or bone mass in JIA are lacking.
2.9.2 Relationship of adipose tissue with disease activity in juvenile 
idiopathic arthritis  
Very little data are available on the relationship between adiposity and disease 
activity in JIA or other paediatric rheumatic diseases. No relationship between 
fat mass or BMI and disease activity in JIA has been observed (Caetano et al. 
2012, Pelajo et al. 2012). Even less is known about the role of adipokines in 
paediatric rheumatology. Patients had elevated leptin levels, but no relationship 
existed between leptin or adiponectin and disease activity in paediatric SLE (Al 
et al. 2009). These relationships have not been previously evaluated in JIA. 
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3. AIMS OF THE STUDY 
Patients with JIA are exposed to complicated interactions between a chronic 
inflammatory disease and adipose tissue-related factors that may have an 
effect on bone health. The clinical significance and characteristics of these 
interactions remain inadequately characterized. These research questions 
constitute the basis for this thesis. Specific aims for the study were as follows: 
1. To assess the prevalence of vertebral compression fractures and contributing 
risk factors in patients with severe JIA
2. To evaluate spinal MRI findings in children with severe JIA
3. To assess body composition and its relationship with bone mineral density 
in JIA. 
4. To explore interactions between circulating adipokines and bone turnover 
markers in patients with severe JIA 
5. To evaluate interactions between adipokines, bone mineral density and 
disease activity in JIA.
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4. PATIENTS AND METHODS
4.1 Study design and data collection
We recruited two patient cohorts for our cross-sectional studies: One cohort 
from the Rheumatism Foundation Hospital in Heinola, a tertiary centre for 
complicated paediatric rheumatology patients in Finland, and another cohort 
from Children’s Hospital, Helsinki University Central Hospital. Both cohorts 
included consecutive patients with JIA, diagnosed with the revised criteria 
(Petty et al. 2004) and fulfilling study inclusion criteria (Table 2).
TABLE 2. Inclusion criteria for the two cohorts of patients with JIA.
Severe JIA Cohort (N=50) GC-treated Cohort (N=50)
1) History of refractory disease with continu-
ous disease activity or recurrent flares requiring 
permanent antirheumatic medication since JIA 
diagnosis
1) JIA diagnosis ≥ 2 years prior to recruitment
2) Systemic glucocorticoids ≥ 3 months
3) age 7-<19 years
2) age < 19 years
3) polyarticular JIA* ≥ 5 years or
4) systemic arthritis ≥ 3 years
* Polyarthritis, extended oligoarthritis or psoriatic arthritis with ≥ 5 affected joints
The Severe JIA Cohort was recruited during an 18-month period. Of the 55 
consecutive patients fulfilling the inclusion criteria, 5 patients declined due 
to lack of interest, and thus, the final study cohort comprised 50 patients. The 
non-participants did not differ from those who consented (with regard to 
diagnosis, disease duration, duration of GC therapy, height or weight). 
The original GC-treated Cohort comprised 62 patients (Valta et al. 2007). 
Because no controls aged below 7 years were available, patients younger than 
7 years (8 patients) or with incomplete whole-body DXA data (4 patients) were 
excluded from the study; the final study cohort thus comprised 50 patients. 
For body composition and adipokine studies (III and IV), one to two controls 
of similar age and gender were chosen for both JIA cohorts from an original 
cohort of 202 apparently healthy Finnish schoolchildren (aged 7-19 years, 62% 
girls) from the Helsinki district (Pekkinen et al. 2012). For the Severe JIA Cohort, 
altogether 89 matching controls (2 for each boy; one  for 11 girls and 2 for 
30 girls), and for the GC-treated Cohort 88 matching controls (one for 3 boys 
and 2 for 13 boys; one for 9 girls and 2 for 25 girls) were found. All study 
participants were Caucasians. 
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4.2 Methods
The study protocol included clinical assessment, questionnaires, biochemistry, 
radiograph of the left hand for bone age assessment and bone densitometry. 
In the Severe JIA Cohort, spinal radiographs and spinal MRI were also 
obtained. Controls were similarly evaluated for background characteristics, 
anthropometric data and bone densitometry, but without radiography of 
the left hand or spinal imaging. Biochemical evaluation also partially differed 
between patients and controls.
4.2.1 Clinical assessment
The patients’ medical records were reviewed for disease and treatment 
characteristics. The cumulative systemic GC dose, as prednisolone equivalents, 
was calculated for the preceding three years to determine recent GC exposure 
for the Severe JIA Cohort and total duration of GC therapy for the GC-treated 
Cohort. Patients were clinically evaluated by a paediatric rheumatologist. 
Height, weight, BMI (kg/m²), number of active joints (including swollen joints 
and tender joints with limited range of motion), physician’s global assessment 
of disease activity and patient’s global assessment of overall well-being on 
the visual analogue (VAS) scale (0-100 mm) were recorded. Overweight and 
obesity were defined according to WHO guidelines as BMI Z-score >+1.0 and 
>+2.0, respectively (www.who.int 2007). Pubertal maturation was clinically 
assessed according to Tanner (1962) in patients, but was based on assessment 
of serum gonadotropin and sex steroid concentrations in controls. Inactive 
disease on medication, i.e. no signs of disease activity during the last six 
months, was defined according to Wallace et al. (2004); all patients received 
antirheumatic medication. Juvenile Arthritis Disease Activity Score (JADAS) 
for 10 or 71 joints was calculated (Consolaro et al. 2009). Childhood Health 
Assessment Questionnaire (CHAQ; Pelkonen et al. 2001) and questionnaires 
on the patient’s physical activity, back pain and fracture history were filled 
out by the patients and their parents. Fractures were regarded as high-energy 
fractures when involving a fall from >3 m or an accident with a motorized 
vehicle; other fractures were regarded as low-energy fractures. In the Severe 
JIA Cohort, diet was assessed by a three-day dietary recall, including two work 
days and one weekend day (completed by 68% of patients). Average daily 
intakes of calcium, phosphate, vitamin D, energy and protein were calculated 
by a registered dietician with the computer program DIET32, version 1.4.4.1 
(Aivo Finland Corp., Turku, Finland).  
Disease and treatment characteristics are presented in Tables 3-5. In comparison 
with the GC-treated Cohort, patients in the Severe JIA Cohort were very young 
at disease onset (median 2.3 years), had longer disease duration and higher 
parameters of disease activity, and a higher proportion of the patients had 
active disease during the last six months (Wallace et al. 2004). The two patients 
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with inactive disease on medication had had refractory disease during their 
disease course of 10 or 14 years. (Table 3) All but three patients in the Severe 
JIA Cohort had received biological therapies (etanercept 23, infliximab 9, 
adalimumab 12, anakinra 5 and rituximab 3 patients), and 65% of the patients 
had a history of two or more biologicals. Multiple drug combinations had been 
used, and even thalidomide and chlorambucil had been given to 4 patients. In 
the GC-treated Cohort, 38% of the patients had received TNF-α antagonists. 
Data on systemic GC exposure and antirheumatic medication at the time of the 
study are presented in Tables 4 and 5, respectively. All patients in the Severe JIA 
Cohort had been given several (median 102) intra-articular GC injections during 
their disease course, and some had received additional injections at their local 
hospital. In the GC-treated Cohort, 92% of the patients had received intra-
articular GC injections (median 7) during their disease course. Six patients with 
severe JIA (three of them with systemic arthritis) had received bisphosphonates 
(BPs) (alendronate 1, zoledronate 1 and pamidronate 4 patients) for 7-37 
months because of compression fractures (4), low BMD and significant fracture 
history (1) or low BMD accompanied by constantly active disease and high-dose 
GC therapy (1). Four patients were still on BP therapy at the time of the study. 
One patient had received alendronate for one month 4.5 years earlier; this was 
considered insignificant regarding the bone health parameters. 
TABLE 3. Disease characteristics in JIA Cohorts. Values are given as median (range) or N (%). 
Disease characteristic Severe JIA Cohort (N=50) GC-treated Cohort (N=50)
Age at diagnosis 2.3 (1.1-11.8) 4.7 (1.1-15.3)
Disease duration 10.2 (3.9-16.8) 6.3 (2.0-15.1)
ANA positive, n (%) 13 (26) 11 (22)
Iritis, n (%) 22 (44)          15 (30)
JIA subtype, n (%)
   oligoarthritis, persistent 0 4 (8)
   oligoarthritis, extended 14 (28) 14 (28)
   polyarthritis, rf- 27 (54) 29 (58)
   polyarthritis, rf+ 1 (2) 1 (2)
   psoriatic arthritis 2 (4) 0
   systemic arthritis 6 (12) 2 (4)
Biologicals previously, n (%) 47 (94%) 19 (38%)
Systemic GC previously, n (%) 47 (94%) 50 (100%)
Active disease, n (%) * 48 (96%) 21 (42%)
* Active disease on medication according to Wallace et al. (2004). GC, glucocorticoid. 
Two patients from the Severe JIA Cohort had celiac disease and were on a gluten-
free diet.
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TABLE 4. Data on systemic (peroral or intravenous) glucocorticoid (GC) therapy; 
values are given as median (range).
Characteristic Severe JIA Cohort (N=50) GC-treated Cohort (N=50)
GC time, years 7.1 (0-15.5) 2.2 (0.25-12.5)
Total cumulative GC dose, g 2.9 (0.5-21.2)
Recent 3-year GC dose, g 3.2 (0-33.3)
Total cumulative GC dose, mg/kg 102 (11-1095)
Recent 3-year cumulative GC dose, mg/kg 72 (0-911)
Current GC dose, mg/d 3.1 (1.25-65.0)* 2.5 (1.25-10.0)**
Current GC dose, mg/kg/d 0.07 (0.02-0.7)* 0.05 (0.02-0.3)**
*n=26 and **n=20  
TABLE 5. Antirheumatic medication at the time of the study.
Medication Number of patients (%)
Severe JIA Cohort (N=50) GC-treated Cohort (N=50)
Methotrexate 28 (56) 38 (76)
Hydroxychloroquine 14 (28) 11 (22)
Sulfasalazine 6 (12) 2 (4)
Azathioprine 9 (18) 0
Cyclosporine A 1 (2) 0
Leflunomide 12 (24) 5 (10)
Sodium aurothiomalate 1 (2) 0
Biologic agents 45 (90) 16 (32)
     TNFα antagonists
          Etanercept 23 (46) 4 (8)
          Infliximab 9 (18) 7 (14)
          Adalimumab 12 (24) 5 (10)
     Anakinra 1 (2) 0
Glucocorticoids 26 (52) a 20 (40)
Thalidomide 1 (2) 0
a Four patients (8%) on daily regimen, others on alternate day regimen. TNFα, 
tumour necrosis factor alpha.
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4.2.2 Imaging studies
Dual-energy X-ray absorptiometry
Bone area (cm²), BMC (g) and areal BMD (g/cm²) for lumbar spine (LS; L2-4), 
total hip and whole body (WB), as well as body composition, were assessed 
with DXA. In the Severe JIA Cohort, DXA measurements were assessed with 
Lunar (Lunar Prodigy; GE Lunar, Madison, WI, USA). In the GC-treated Cohort 
and in controls, Hologic (Hologic Discovery A, Waltham, MA, USA) was used. 
For Studies I and II, in the absence of a control group, DXA results of the Severe 
JIA Cohort were compared with published reference values to calculate BMD 
Z-scores (van der Sluis et al. 2002). For body composition analyses, DXA results 
of both patient cohorts were compared with those of matched controls. To 
enable comparison of results between the Severe JIA Cohort and controls, the 
data for controls were cross-calibrated according to Shepherd et al. (2012). 
BMD Z-scores for the GC-treated Cohort and controls were calculated according 
to equipment-specific reference values that have previously been shown to 
be appropriate for Finnish children (Valta et al. 2009). DXA and bone age 
radiograph were not obtained for one patient in the Severe JIA Cohort with 
severe carpal deformities, extreme growth failure and multiple compression 
fractures. As vertebral fractures are likely to reduce height and because bone 
age delay is a common complication of JIA, we chose to adjust DXA results 
not with height but with bone age. Height, age and bone age-adjusted bone 
mineral content-to-lean tissue mass (BMC/LTM) ratios were calculated according 
to Högler et al. (2003) for the Severe JIA Cohort. 
Spinal radiography
Thoracolumbar radiographs (antero-posterior and lateral projections) 
were obtained and analysed for compression fractures by two experienced 
radiologists (paediatric radiologist and orthopaedic radiologist), who were 
blinded to the patients’ clinical diagnosis and status. They analysed the 
radiographs first individually, and the results were combined for consensus. 
The less severe  alternative was reported as the final conclusion when individual 
readings differed. Compression fractures were classified according to Mäkitie 
et al. (2005); a ≥20% vertebral height reduction was regarded as signifying 
vertebral compression.  Compromised visibility partially prevented evaluation 
of the thoracic spine in 7 patients. Previous spinal radiographs were also 
retrospectively analysed for vertebral morphology.
Bone age was determined according to Greulich-Pyle (1959) from the patient’s 
left hand radiograph and considered delayed/advanced when it differed from 
calendar age by more than one year.
Spinal magnetic resonance imaging
MRI examinations of the thoracic and lumbar spine were performed with an open-
field 0.23 T MRI unit (Panorama Power, Philips Medical Systems, Vantaa, Finland) 
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with a spine coil. Sagittal images with 5 mm slice thickness were obtained with 
T1-weighted turbo spin echo (TR 475.4-500 ms, TE 13 ms, flip angle 90, FOV 360) 
and T2-weighted turbo spin echo (TR 3987-4118, TE 108, flip angle 90, FOV 360) 
sequences. In most of the patients, the thoracic spine and the lumbar spine were 
imaged separately; only in the youngest and smallest patients were they imaged 
together. One of the patients had undergone MRI in a 1.5 T imager (Philips Intera 
Achieva, Philips Medical Systems, Best, the Netherlands) in another hospital at the 
time of the study, and these images were used in the analysis.
All MRI images were analysed by the same radiologists and with similar 
principles as spinal radiographs. The assessment included the vertebrae, 
intervertebral discs, spinal canal and neural foramina, back muscles and 
abdominal subcutaneous adipose tissue, as described below.
Assessment of vertebrae and endplates. Vertebral bodies were evaluated for 
shape and signal intensity. The vertebrae were classified as normal, wedged 
or compressed according to Mäkitie et al. (2005). The location of defects in 
vertebral corners was noted and recorded as i) anterior vertebral corner defects 
or ii) posterior vertebral corner defects. Endplate irregularities and Schmorl 
nodes were recorded. Endplates were regarded as irregular when the entire 
endplate was involved; Schmorl node (herniation of the intervertebral disc into 
the endplate and the adjacent vertebral body) was characterized by a focal 
endplate defect. 
Assessment of intervertebral discs. Intervertebral disc height and signal 
intensity were assessed from T2-weighted sagittal image. The discs were 
classified as grade 0 (normal), grade 1 (mild degeneration) and grade 2 (severe 
degeneration). Increased disc height with normal signal intensity (“ballooning” 
of a disc) was noted, if present. Disc herniations were classified as a protrusion 
(slight bulging beyond the interspace) or a prolapse (extrusion beyond the 
interspace).
Assessment of spinal canal. Medulla and cauda equina were evaluated for shape 
and signal intensity. The width of the spinal canal in T2-weighted images was 
graded as grade 0 (normal), grade 1 (mild narrowing), grade 2 (spinal stenosis) 
or grade 3 (compression of the medulla). Neural foramina and neural root 
compression in T1-weighted sagittal images was classified as grade 0 (normal), 
grade 1 (mild narrowing without impingement of the neural root) or grade 2 
(severe narrowing with impingement of the neural root).
Assessment of lumbar back muscle. The lumbar muscular was assessed visually. 
Apparent size loss on TI-weighted images and high signal intensity streaks 
on T1- and T2-weighted images representing fat deposits in the muscle were 
recorded. The findings were classified as grade 0 (normal), grade 1 (mild 
atrophy) or grade 2 (severe atrophy). 
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4.2.3 Biochemistry
Blood samples were drawn in the morning between 8:00 and 11:00 and 
second void urine samples were collected after an overnight fast and stored 
at -80°C until analysed. Biochemical assessments with abbreviations and 
applied methods are presented in Table 6. Numerals I-IV refer to the number 
of the study. Parameters with unspecified methods were analysed by standard 
methods and compared with reference values.  For urine calcium-to-creatinine 
ratio (U-Ca/Cr), values <0.7 mmol/mmol were considered normal. Vitamin D 
status was defined based on 25-OHD value as severe deficiency (<12.5 nmol/l), 
deficiency (<37.5 nmol/l), insufficiency (37.5-<50.0 nmol/l) or sufficiency (≥50 
nmol/l) (Misra et al. 2008). 
TABLE 6. Biochemical assessment in patient cohorts and controls in Studies I-IV. 
ALP, alkaline phosphatase; OC, osteocalcin; PINP, aminoterminal propeptide 
of type I collagen; ICTP, carboxyterminal telopeptide of type I collagen; FSH, 
follicle-stimulating hormone; LH, luteinizing hormone; CMIA, chemiluminescent 
microparticle immunoassay; ELISA, enzyme-linked immunosorbent assay. 
* Severe JIA Cohort, ** GC-treated Cohort, ^ (Käkönen 2000, Paldanius 2012)
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Severe JIA 
Cohort
Controls I GC-treated 
Cohort
Controls II Method
Erythrocyte sedimentation rate, ESR I-III IV
C-reactive protein, CRP I-III
S-Calcium, Ca; ionized calcium, Ca-ion I
P-Inorganic phosphate, Pi I
P-Parathyroid hormone, PTH I Immunoluminometric method 
S-25-hydroxyvitamin D, 25-OHD I Radioimmunoassay 
S-Insulin-like growth factor-1, IGF-1 I Immunoluminometric method 
FSH, LH (girls >8 years, boys >10 years) I-III III IV IV CMIA* / Immunofluorometric method**
Oestradiol (girls >8 years) I-III III IV IV Radioimmunoassay 
Testosterone (boys >10 years) I-III III IV IV CMIA* / Liquid chromatography 
mass spectrometry**
Bone turnover markers
S-OC         (marker of bone formation) III III Two-site immunoassay based on 
monoclonal antibodies^
S-ALP        (marker of bone formation) III III Standard kinetic method 
S-PINP       (marker of bone formation) III III Radioimmunoassay 
S-ICTP       (marker of bone resorption) III III Radioimmunoassay 
Adipokines
S-Leptin III III IV IV Human leptin ELISA 
S-Adiponectin III III IV IV Human adiponectin ELISA 
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4.3 Ethical considerations
A written informed consent was obtained from all study participants and their 
parents. The study protocol was approved by the Research Ethics Committee 
of Helsinki University Central Hospital. Spinal radiographs were considered 
clinically appropriate for patients from the Rheumatism Foundation Hospital 
because they had severe disease and were at risk of vertebral compression 
fractures. The radiation dose from DXA is very low and absent in MRI. No 
sedation for MRI studies was required. 
4.4 Statistics 
Descriptive data are reported as median with range or interquartile 
range (IQR), or as mean ± standard deviation (SD) or with 95% confidence 
interval (CI). Simple regression analysis was used for correlations (Pearson or 
Spearman), the unpaired two-tailed Student’s t-test for comparing means and 
the Mann-Whitney U-test for comparing non-normally distributed variables. 
The Chi-square test (or Fischer’s exact test) was applied when nominal data 
were compared. Comparison of groups with adjustments was performed 
with analysis of variance (ANOVA). The association of adipokines with bone 
turnover markers or bone mass was analysed by linear regression (additive 
models). Logarithmic transformations for non-normally distributed data were 
used as appropriate. To avoid errors related to multiple testing, Bonferroni 
correction was used (Study III); the required significance level depended on the 
number of predictors in the model.  A multivariate logistic regression model 
was used to identify and determine odds ratios with 95% CI for significant 
associations with compression fractures. Factors included in logistic regression 
analysis were dichotomized based on the value’s distribution in the cohort 
or by clinically relevant cut-offs. A P-value of less than 0.05 was considered 
statistically significant.
Statistical analyses were performed either with Statview® 5.0.1 for Macintosh, 
1992-1998; SAS Institute (Studies I and II) or with SPSS for Windows version 17.0 
or 21.0 (SPSS Inc., Chicago, IL, USA) (Studies III and IV). 
Lumbar DXA data of two patients in the Severe JIA Cohort and one patient in 
the GC-treated Cohort were excluded from analyses because of compression 
changes in the lumbar spine. In the Severe JIA Cohort, altogether six patients 
had received previous bisphosphonate therapy (one of them was not evaluated 
for DXA or bone turnover markers because of severe skeletal changes and 
extreme growth failure), and their results were excluded from the analyses 
evaluating bone mineral density or bone turnover markers.
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5. RESULTS 
5.1. Clinical and disease characteristics 
5.1.1 Anthropometric data and disease activity
The two cohorts with JIA were significantly different from each other. 
Anthropometric data showed growth delay, higher BMI Z-score and higher 
percentages of overweight and obesity in the Severe JIA Cohort when 
compared with healthy controls. In the GC-treated Cohort, Z-scores for height 
and BMI were similar to controls. Patients in the Severe JIA Cohort were older 
than in the GC-treated Cohort (median age 14.8 years vs. 12.4 years) (Table 7). 
Parameters of disease activity at the time of the study are presented in Table 8. 
As expected based on inclusion criteria, patients in the Severe JIA Cohort had 
higher disease activity values than their counterparts in the GC-treated Cohort. 
When patients with systemic disease were excluded, median JADAS-10 scores 
remained similar (6.0 in Severe JIA Cohort and 2.5 in GC-treated Cohort).
TABLE 7. Anthropometric data in the JIA cohorts and in healthy controls. Data are 
given as median (range) or proportion (%). 
* According to World Health Organization. P-values were determined with the 
Mann-Whitney U-test or the Chi-square test, as appropriate. One 14-year-old 
girl with extreme growth failure (height Z-score -9.4) and multiple compression 
fractures was excluded from Study III.   
RESULTS
Severe JIA 
Cohort
N=49
Controls I
N=89 p
GC-treated 
Cohort
N=50
Controls II
N=88 p
Boys / girls, % 18 / 82 20 / 80 0.792 32 / 68 33 / 67 0.908 
Age, years 14.8 (7.0-18.7) 14.5 (7.4-18.8) 0.569 12.4 (7.2-17.9) 12.7 (7.4-17.4) 0.702
Pre-/mid-/postpubertal, % 18 / 30 / 52 25 /23 / 52 0.442 36 / 36 / 28 38 / 26 / 36 0.421
Height Z-score -1.2 (-4.1- +1.9) -0.1 (-2.3-+2.6) <0.001 0.1 (-2.9-+1.5) 0.2 (-2.0-+2.8) 0.313
Height-adjusted weight, % +24 (-15- +123) +4 (-25-+53) <0.001 +5 (-17-+49) +2 (-20-+51) 0.281
BMI, kg/m2 22.2 (14.6-39.2) 19.2 (13.0-28.5) <0.001 18.9 (13.2-30.0) 18.4 (13.6-29.0) 0.509
BMI Z-score +0.8 (-1.6-+4.3) -0.1 (-3.5-+2.5) <0.001 0.2 (-1.9-+2.3) 0.0 (-2.2-+2.5) 0.321
Overweight, n (%)* 19 (39) 13 (15) 0.001 10 (20) 14 (16) 0.542
Obese, n (%)* 14 (29) 1 (1) <0.001 5 (10) 3 (3) 0.113
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TABLE 8. Parameters of disease activity as median (range) at the time of the study. 
Parameters of disease activity Severe JIA Cohort (N=50) GC-treated Cohort 
(N=50)
   Number of active joints              1 (0-38)                                           0.0 (0-8)
   Physician’s global assessment 20 (0-70) 5.0 (0-80)
   Patient’s global assessment 14 (0-67)                           3.5 (0-87)
   CHAQ 0.125 (0 – 2.375) 0.0 (0-1.625)
   ESR, mm/h                  12 (3-71) 8.5 (2-65)
   CRP 5 (2-129)
   JADAS-10* 6.0 (0-23.6) 2.4 (0-18.3)
* JADAS, juvenile arthritis disease activity score; values between 0 and 40. Score 
≤1.0 indicates inactive disease (Consolaro et al. 2014).
5.2 Bone health 
5.2.1 Dietary data and biochemistry in the Severe JIA Cohort 
A three-day dietary recall was completed by 34 patients (68%). The reported 
median energy intake was 73% of the daily recommended intake (DRI), which 
is likely to be an underestimate considering the high BMI observed in these 
patients. A wide variation existed between patients regarding their reported 
total intakes of calcium and vitamin D, but the intakes on average exceeded 
minimal recommendations. Calcium and vitamin D supplements were utilized 
by 47% and 59% of the patients, respectively. Dietary data are presented 
in Table 9. The median serum 25(OH)D was 53 (range 20-95) nmo/l. Vitamin 
D concentration was sufficient in 62%, insufficient in 24% and deficient in 
14% of patients; only one patient had a value >80 nmol/l. Mild hypercalciuria 
(U-Ca/Cr >0.7 mmol/mmol) was observed in 5 patients. None of the patients 
had hypercalcaemia and 2 had mild hypocalcaemia. Occasional patients had 
hypophosphatemia (n=2), hyperphosphatemia (1) and slightly subnormal (1) or 
supranormal (1) fP-PTH values. S-IGF-1 was subnormal in 7 patients.
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TABLE 9. Dietary data for 34 patients with severe JIA.
Median Range
Calcium intake from diet, g/day 1.09 0.19-2.82
Calcium intake including supplements, g/day 1.34 0.23-3.32
Calcium intake including supplements, % of DRI* 155 25-383
Vitamin D intake from diet, ug/day 4.7 1.2-13.7
Vitamin D intake including supplements, ug/day 14 1.2-34
Vitamin D intake including supplements, % of DRI* 187 16-453
                                                               % of 2014 DRI** 140 12-340
Phosphate intake, % of recommendation 189 63-540
Dietary energy, % of recommendation 73 36-131
Dietary protein, Energy-% 16.1 12-25.1
* Finnish National Nutrition Council dietary recommendations from the year 2005 
** The recommended daily vitamin D intake increased from 7.5 to 10 μg in the year 
2014. DRI, daily recommended intake
5.2.2 Bone mineral density 
Patients in the Severe JIA Cohort had decreased median BMD Z-scores for 
the lumbar spine (-0.8) and whole body (-1.0), but Z-scores for bone age- and 
height-adjusted BMC-to-lean mass ratios were normal. In the GC-treated 
Cohort, Z-scores for BMD values and BMC-to-lean mass ratio were lower than 
in controls (Table 10). DXA results between patient cohorts are not comparable 
because measurements were performed with different DXA devices. BMD did 
not correlate with current disease activity or cumulative GC dose in either cohort, 
but an inverse correlation was observed in the GC-treated Cohort between 
the current weight-adjusted GC dose and WB BMD (rs=-0.304, p=0.032); a 
similar trend was observed regarding LS BMD (rs=-0.272 and p=0.059). Similar 
correlations for the current weight-adjusted GC dose with Z-scores for LS BMD 
(rs=-0.382, p=0.011) and WB BMD (rs=-0.330, p=0.029) were seen in the Severe 
JIA Cohort.  
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Bone variable Severe JIA Cohort*
N=44
GC-treated Cohort**
N=50
Controls**
N=88 p-value#
LS aBMD Z-score, for bone age -0.8 (-1.3, 0.0) -0.5 (-1.2, +0.6) 0.0 (-0.5, +0.6) 0.006
WB aBMD Z-score, for bone age -1.0 (-1.6, -0.3) -0.2 (-0.9, +0.8) 0.1 (0.0, +0.8) 0.009
BMC/lean mass 0.053 (0.050, 0.060) 0.051(0.048, 0.054) 0.053 (0.050, 0.056) 0.002
          for height, Z-score +0.1 (-1.0, +1.0)
          for age, Z-score -0.3 (-1.0, +0.9)
          for bone age, Z-score +0.2 (-1.0, +1.1)
TABLE 10. DXA data in the Severe JIA Cohort as well as in the GC-treated Cohort 
with controls. Data are presented as median (IQR). 
* Lunar, ** Hologic. # Comparison between GC-treated Cohort and controls (Mann-
Whitney U-test). LS, lumbar spine; WB, whole body; BMC, bone mineral content 
5.2.3 Non-vertebral fractures in the Severe JIA Cohort 
Altogether 16 patients (32%) had had previous significant (i.e. excluding finger 
and toe fractures) peripheral low-energy fractures. Nine patients had had only 
one fracture, 5 patients had 2 previous fractures, one patient had 3 previous 
fractures and one patient had 4 previous fractures. Two patients with non-
vertebral fractures were considered to have significantly compromised bone 
health based on a significant fracture history and low BMD (Z-score ≤-2.0), thus 
fulfilling the ISCD criteria for paediatric osteoporosis (Rauch 2008).
5.2.4 Vertebral fractures in the Severe JIA Cohort 
Radiographic findings 
Five patients had a history of earlier vertebral compressions at some point 
after JIA diagnosis; all had received bisphosphonates. At the time of the 
study, altogether 11 patients (22%) had vertebral compression fractures on 
spinal radiographs. Fractures were mostly (38 of 54 fractures, 70%) located in 
the thoracic area. Eight patients had more than one (from 2 to 16) fractured 
vertebra. Visibility of the vertebrae was suboptimal in the thoracic spine of 7 
patients. In Figure 9, multiple compressed vertebrae in the thoracic and lumbar 
spine and densitometry data in a 9-year-old boy with systemic arthritis are 
shown.
Associations between clinical factors and vertebral fractures
Age and height Z-score were not significantly different between those with 
and without fractures. Patients with fractures had higher BMI Z-score than 
those without fractures, but the difference was not significant between the 
groups regarding fat percentage. Disease duration was shorter, but excluding 
the active joint count, parameters of disease activity were higher in those with 
fractures. There was no difference concerning the total duration of GC therapy 
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between the groups, but the cumulative 3-year and current GC doses adjusted 
for weight were higher in those with fractures. Z-scores for LS and WB BMD 
did not differ between the groups. The reported daily intake of vitamin D 
was higher in patients with fractures, but 25-OHD values were similar. Two 
patients with compression fractures had never had back pain, and only one 
patient had back pain daily. No difference was present in the number of non-
vertebral fractures between patients with and without vertebral fractures. 
Factors associated with vertebral fractures are shown in Table 11. 
In logistic regression analysis, cumulative weight-adjusted GC dose, CHAQ 
and BMI Z-score were chosen for further analysis. Cumulative GC dose of >75 
mg/kg (48% of patients) was associated with a 7-fold risk (OR 7.2, p=0.016), 
CHAQ >0.5 (consistent with moderate disease activity; 22% of patients) with 
a 7-fold risk (OR 7.2, p=0.013) and BMI Z-score >+2.0 (28% of patients) with 
an almost 5-fold risk (OR 4.7, p=0.052) for compression fractures. Cumulative 
GC correlated with CHAQ (r=0.29). In stepwise backward analysis, the most 
significant associations with compression fractures were with CHAQ (OR 16.4, 
p=0.005) and BMI Z-score (OR 1.89, p=0.029), which together explained 45% 
of the fracture risk. 
  Thoracic spine      Lumbar spine                             Bone densitometry
FIGURE 9. Spinal radiographs and bone densitometry in a 9-year-old boy with 
systemic arthritis. Multiple compressed vertebrae in the thoracic and lumbar 
spine were observed. Vertebrae Th 4 and 6 were totally collapsed (3b) (arrow), 
and grade 2b-3a fractures were observed in vertebrae Th5 and Th7-L5. Because 
of bisphosphonate therapy, vertebrae have sclerotic margins and are therefore 
more visible. Lumbar spine DXA results of the same patient show rather high BMD 
values, resulting from bisphosphonate therapy and compression changes in the 
measurement area.
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TABLE 11. Factors associated with vertebral fractures.
Clinical characteristic No fractures
(n=39)
With fractures
(n=11)
p
 
Demographics and anthropometry
   Sex distribution, boys n (%)  5 (13) 4 (36) 0.073
   Age, mean ± SD, years 14.4 ± 3.0 13.6 ± 2.8 0.390 
   Height Z score, mean ± SD -1.3 ± 1.2 -1.9 ± 2.8 0.480
   BMI Z-score, mean ± SD +0.7 ± 1.4 +1.9 ± 1.6 0.029 
   Fat %, mean ± SD 35 ± 9.9 41.5 ± 9.6 0.187
Disease characteristics (mean ± SD)
   Disease duration, years 11.1 ± 3.6 8.2 ± 3.5 0.032 
   Number of active joints 2.1 ± 2.3 6.0 ± 11.2 0.670 
   CHAQ a 0.24 ± 0.31 0.80 ± 0.70 0.004
   ESR, mm/h 14.2 ± 13.8 26.9 ± 22.8 0.047 
   JADAS-10 5.8 ± 4.7 11.4 ± 8.3 0.024
GC treatment (mean ± SD)
   Total duration of GC therapy, years 7.1 ± 4.1 7.5 ± 3.5 0.910 
   Recent 3-year cumulative GC dose, mg/kg  69 ± 67 292 ± 323 0.012 
   Current weight-adjusted GC dose, mg/kg/day 0.04 ± 0.06 0.14 ± 0.22 0.037 
Skeletal characteristics and nutrition
   LS BMD Z-score, mean ± SD b -0.7 ± 0.9 -0.7 ± 1.6 0.63 
   WB BMD Z-score, mean ± SD b -1.1 ± 1.0 -0.8 ± 1.1 0.53 
   BMC/LBM for height Z-score, mean ± SD b +0.1 ± 1.5 -0.6 ± 2.2 0.33
   Ca intake, % of DRI 158 (76) 212 (98) 0.154
   Vitamin D intake, % of DRI 162 ± 130 282 ± 153 0.044
   S-25-OHD, nmol/l 53.6 ± 15.8 59.5 ± 10.9 0.170
Statistical significance determined by the Mann-Whitney U-test, Chi-square test or 
Fischer’s exact test as appropriate. 
a Childhood Health Assessment Questionnaire, 0 = best and 3 = worst; data of 46 
patients aged <18 years.
b Values are corrected for bone age. Data of 44 patients; five patients with previous 
bisphosphonate treatment (3 with and 2 without vertebral fractures) were omitted 
from the analyses, and BMD was not available for one patient.
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Magnetic resonance imaging 
Altogether 62% of the patients had one or more spinal abnormalities on MRI. 
Vertebral fractures were observed in 14 patients (28%). The total number of 
deformed vertebrae was 66 (1-16 affected vertebrae per patient). Altogether 
61% of these were located in the lower thoracic spine (vertebrae Th7-Th12), 
18% in the upper thoracic spine (Th1-Th6) and 21% in the lumbar spine (L1-
L5). 
5.2.5 Other skeletal findings on magnetic resonance imaging 
 
Altogether 26% of the patients had endplate irregularities, 16% had anterior 
vertebral corner lesions and 46% had disc changes (entire or focal). The majority 
(70%) of endplate changes and disc changes (54%) were located in the lower 
thoracic spine, but 35% of the disc changes were observed in the two lowest 
lumbar disc spaces. Three patients with severe vertebral compression fractures 
had ballooning of the intervertebral discs. Two patients had mild spinal canal 
narrowing without medullar involvement; none had neural root compression. 
Figure 10 A shows normal vertebral morphology, and Figures 10 B-D and 11 
A-C present abnormal vertebral findings on MRI.
Mostly non-significant differences were present between patients with and 
without MRI findings. Boys had more vertebral fractures than girls, but no gender 
difference was noted regarding other changes. Relative to subjects without 
spinal abnormalities, BMI Z-score tended to be higher in those with various 
spinal abnormalities such as fractures (p=0.160), endplate changes (entire or 
focal, p=0.015), anterior corner lesions (p=0.093) and disc changes (p=0.139). 
Patients with spinal fractures tended to have higher 3-year cumulative GC dose 
(p=0.086), but similar associations with GC dose were not observed concerning 
other spinal changes. 
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A                                                                             B
FIGURE 10. A. Normal vertebral morphology in a 15-year-old girl with extended 
oligoarthritis on MRI and spinal radiography. B. The thoracic spine was poorly 
visible on radiography in this 13-year-old boy with systemic arthritis. Vertebrae 
Th1-10 could not be reliably assessed, and only a wedge fracture (Grade 2a) 
at Th12 (open arrow) was seen on radiography, while multiple fractures in the 
thoracic spine were visible on MRI. Vertebra Th5 was totally collapsed (arrow), 
and Grade 3a compressions were observed at Th 4, 6-10. In Th12 vertebra, also 
a focal irregularity (Schmorl, thin arrow) in the lower endplate was observed. A 
mild increase in disc height (arrowheads) resulting from endplate depression in 
adjacent vertebrae was also seen.   
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C                                                                                                                D
          
                                                                                                                     
FIGURE 10. C. Multiple vertebral fractures in the thoracic and lumbar spine of a 
9-year-old girl with systemic JIA. In Th11-L4 intervertebral disc spaces, a slight 
increase in height of the discs with normal signal intensity (bright) and in the 
presacral disc a protrusion (arrowhead) and decreased signal intensity (dark, thin 
arrow) are seen. Lumbar radiograph also shows wedge deformities (L1 2b, L2 2a, 
arrow) and compression deformities (L3-5 3a, open arrow). Sclerotic vertebral 
margins are due to bisphosphonates. D. All subcervical vertebrae except L5 in a 
14-year-old girl with treatment-resistant psoriatic arthritis are severely compressed 
(Grade 3b), and all intervertebral discs are markedly ballooned. Compressions in 
the thoracic spine are visible also in radiography, although bone seems severely 
osteoporotic. 
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A                                      B                                              C
FIGURE 11. Findings on spinal MRI in patients with severe JIA. 
A. A corner defect in the lower anterior corner of L1 (arrow) in a 12-year-old girl 
with seronegative polyarthritis. 
B. Anterior longitudinal ligament thickening, disc degeneration (open arrow), 
several small anterior corner defects (arrow) and Schmorl nodes (thin arrow) in a 
16-year-old girl with systemic arthritis. 
C. In a 15-year-old boy with systemic arthritis, wedge fracture in Th12 causes 
kyphosis. On MRI, anterior corner lesions with small bone fragments (arrow) in 
Th10 and Th11, a large corner defect and subchondral bone oedema (Th11-12, 
thin arrow) and irregular endplate and disc degeneration (open arrow) are seen. 
On radiography, Th12 vertebra (arrowhead) was not regarded as fractured, but 
narrowing of disc spaces Th11-L2 and large anterior corner defects of Th11-12 and 
L2 (arrow) were observed.
5.3 Body composition and its relationship with bone 
mineral density
Patients in the Severe JIA Cohort had increased adiposity, as expected based on 
their increased BMI Z-score, but lean mass was similar to controls. In the GC-treated 
Cohort, neither fat mass nor lean mass differed from controls. Body composition 
data for patient cohorts and controls are presented in Table 12. In the GC-treated 
Cohort, data were further analysed by comparing patients according to lumbar 
spine BMD Z-scores; a cut-off value at -1.0 was used (Table 13). When comparing 
the groups according to calendar age-based BMD Z-score, Z-score values below 
-1.0 (“low BMD”) were related to lower Z-scores for height and BMI and to smaller 
bone size and lower lean mass index. However, when bone age-adjusted BMD 
Z-scores with similar cut-off values were compared, except for lower BMC-to-lean 
mass ratio, no differences regarding growth or body composition existed between 
those with low or “normal” BMD. Altogether 60% and 35% of patients in the 
low and normal BMD groups, respectively, had active disease during the last six 
months (p=ns); the median JADAS-10 score reflecting current disease activity was 
similar between the groups (2.4 vs. 2.3, p=ns). 
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TABLE 12. Body composition assessment with DXA for a) the Severe JIA Cohort and 
controls and b) the GC-treated Cohort and controls. 
a) Severe JIA Cohort
median
(N=49)
IQR
Controls* 
median
(N=89)
IQR p-value 
Total fat, % 37.1 30.2-46.0 28.8 23.5-33.2 <0.001
Fat mass, kg 18.96 11.96-25.33 12.98 9.54-17.82 <0.001
FMI, kg/m2 8.5 5.7-12.2 5.5 4.0-6.9 <0.001
Lean mass, kg 29.51 26.16-34.45 31.78 25.51-37.61 0.241
LMI, kg/m2 13.0 12.3-14.2 12.9 11.8-14.0 0.145
b) GC-treated Cohort
median
(N=50)
IQR 
Controls
median
(N=88)
IQR p-value
Total fat, % 27.1 23.0-32.3 26.9 21.2-31.4 0.516
Fat mass, kg 11.99 7.73-16.89 11.97 7.97-15.06 0.693
FMI, kg/m2 5.5 3.7-6.6 5.0 3.7-6.3 0.372
Trunk fat, % 21.4 16.1-26.4 20.9 15.7-25.8 0.830
Trunk fat mass, kg 3.94 2.29-5.82 3.91 2.51-5.43 0.787
Lean mass, kg 31.65 23.09-35.96 30.63 24.91-36.84 0.852
LMI, kg/m2 13.0 11.6-14.8 13.0 11.9-13.9 0.951
* Data for the controls of the Severe JIA Cohort were cross-calibrated. FMI, fat 
mass index; LMI, lean mass index. P-values were calculated with Mann-Whitney 
U-test.
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LS BMD Z-score For calendar age
≤-1.0 SD (n=16) >-1.0 SD (n=33)
For bone age 
≤-1.0 SD (n=15) >-1.0 SD (n=34)
mean  ± SD mean  ± SD p-value mean  ± SD mean  ± SD p-value
Gender, boys/girls (%) 12.5/87.5 39/61 0.097  27/73 32/68 0.750
Age, years 12.3 ± 3.0 12.6 ± 3.2 0.782 12.5 ± 2.7 12.5 ± 3.3 0.896
Pre- / postpubertal, 
n (%)
(44)/(19) (33)/(30) 0.649 33/13 38/32 0.211
Height Z-score -0.56 ± 3.0 +0.15 ± 0.9 0.025 -0.39 ± 1.0 +0.05 ± 1.0 0.158
BMI Z-score -0.48 ± 1.0 +0.48 ± 1.0 0.005 +0.26 ± 1.3 +0.14 ± 1.0 0.544
Fat, % 26.0 ± 6.2 27.7 ± 7.3 0.238 29.1 ± 7.2 26.2 ± 6.8 0.288
Fat mass index, 
kg/m2
4.8 ± 1.7 5.7 ± 2.0 0.162 5.9 ± 2.2 5.2 ± 1.8 0.368
Lean mass index, 
kg/m2
12.4 ± 1.9 13.7 ± 1.9 0.013 13.3 ± 1.9 13.2 ± 2.0 0.696
Bone area/height, 
cm2/m
1223 ± 149 1322 ± 134 0.039 1269 ± 166 1299 ± 137 0.649
BMC/lean mass 0.050 ± 0.004 0.052 ± 0.004 0.125 0.048 ± 0.002 0.052 ± 0.004 <0.001
TABLE 13. Comparison of data for the GC-treated Cohort according to lumbar spine 
BMD Z-score for calendar age or bone age; a cut-off value at -1.0 was used.
BMI, body mass index; BMC, bone mineral content. P-values were calculated with 
Mann-Whitney U-test.
5.4 Serum bone turnover markers and adipokines 
  
In the Severe JIA Cohort, serum bone formation markers did not differ from 
controls. However, bone resorption marker ICTP was significantly higher in 
patients than in controls (mean 15.6 µg/l, 95% CI 13.5-17.4 vs. mean 12.3 µg/l, 
95% CI 11.1-13.6 µg/l; p=0.006) suggesting an imbalance in bone turnover. Serum 
leptin concentration was significantly higher in patients than in controls, even 
when adjusted for age, gender, pubertal stage and fat mass, as shown in Figure 
12. Adiponectin concentrations were similar, but adiponectin-to-fat mass ratio 
was lower in patients than in controls (median 0.53 vs. 0.77, p=0.004). On the 
contrary, in the GC-treated Cohort, leptin and adiponectin values were similar 
to those in controls. 
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FIGURE 12.  Comparison of serum leptin (A) and adiponectin (B) values in patients 
with severe JIA and healthy controls when 1) unadjusted (crude), 2) adjusted 
for age, gender and pubertal stage, 3) adjusted additionally for fat mass. Bars 
designate mean concentrations and whiskers the upper limit of the standard error 
of the mean.
5.4.1 Association of adipokines with serum bone turnover markers
The association between serum adipokines and bone turnover markers as 
standardized beta coefficients was assessed for the Severe JIA Cohort and for 
controls. In controls, inverse associations between leptin and bone turnover 
markers attenuated after adjustment for confounding factors. In patients, by 
contrast, associations became stronger, especially concerning PINP (Table 14), 
but a similar trend was observed concerning other markers when adjusted for 
fat mass. Although not significant, beta coefficients of the patients remained 
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different from controls after adjusting for lean mass and current GC exposure. 
No associations between adiponectin and bone turnover markers were 
observed in either group. 
TABLE 14. Association of serum leptin with serum PINP in the Severe JIA Cohort 
and in healthy controls (an additive model). Data are given as standardized beta 
coefficients and p-values.
Patients (N=44)
[P1NP]
beta p
Controls (N=89)
[P1NP]
beta p
[Leptin]
Unadjusted -0.132 0.394 -0.519 <0.001
Adjusted* -0.143 0.186 -0.202 0.011
+ fat mass -0.513 0.004 -0.130 0.219
+ lean mass -0.371 0.048 -0.082 0.466
+ [GC] -0.349 0.063
Brackets for ln-transformed (non-normally distributed) variables. * adjusted for 
age (controls) or bone age (patients), gender and pubertal status. GC; current 
weight-adjusted GC dose. Statistically significant Bonferroni-adjusted p-values 
appear in boldface.
5.4.2 Association of adipokines with bone mineral density
The association between serum adipokines and whole-body BMD was similarly 
tested in an additive model after adjustments for gender, height, pubertal 
stage and fat mass (lean mass could not be added to the models because of 
multicollinearity). In the Severe JIA Cohort, an inverse association of leptin 
with whole-body BMD existed (beta coefficient -0.370, p=0.042; for Bonferroni 
correction, a required p-value here would be <0.01). The association attenuated 
(beta -0.298, p=0.117) when correction for bone age instead of pubertal stage 
was used. These results were not compared with controls because DXA bone 
data of the controls was not cross-calibrated. Interestingly, in the GC-treated 
Cohort, serum leptin concentration tended to be higher (median 8.2 vs. 5.3 
ng/ml, p=0.064) in those with lumbar spine BMD ≤-1.0 SD than in those with 
higher BMD Z-scores. The result remained similar when adjusted for gender 
and fat mass (p=0.061). However, no association between leptin and BMD 
existed in the GC-treated Cohort or in their controls. Concerning adiponectin, 
no association with BMD appeared in those with severe JIA. At first sight, no 
association existed in the GC-treated Cohort either, but an inverse association 
was observed in their controls (beta -0.127, p=0.047). However, an inverse 
association between adiponectin and BMD appeared also in the GC-treated 
Cohort after adjustment for bone age instead of pubertal stage (beta -0.204, 
p=0.018). 
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5.4.3 Correlation between adipokines and disease activity
Leptin or adiponectin did not correlate with parameters of disease activity in 
either cohort.
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6. DISCUSSION 
JIA predisposes to alterations in body composition and bone health. Several 
contributing factors have been recognized. These include inflammatory cytokines, 
nutritional and hormonal factors, limited physical activity and treatment-related 
effects from GCs. Vertebral compressions indicate pathological skeletal fragility 
and significantly compromised bone health, but may go undiagnosed as they 
are often asymptomatic and may be present despite normal BMD. Increased 
fat mass may also have negative effects on bone health, and furthermore, 
adipose tissue may modify immunity and inflammatory reactions, and thus, 
disease activity, in rheumatic diseases. Fat-derived adipokines are suggested 
to play a key role. We investigated the prevalence, risk factors and diagnostics 
of spinal compression fractures in severe JIA. In addition, we evaluated body 
composition and the relationship of adipokines with bone turnover markers, 
BMD and disease activity in patients with JIA.
6.1 Fractures 
Non-vertebral fractures are common in children; approximately every other boy 
and every third girl sustains one or more fractures during childhood (Landin 
1983, Jones et al. 2002, Mäyränpää et al. 2010). Patients with childhood-onset 
arthritis have even more fractures than their healthy peers (Burnham et al. 
2006a). As with healthy children, at a median age of 14.8 years, 30% of patients 
in our Severe JIA Cohort, with a female predominance, had sustained at least 
one peripheral fracture. Considering the severe disease course of the patients 
and the prevalence of fractures overall in children, this was less than expected. 
However, our findings may at least partly be related to limited opportunities 
for sports and especially high-risk activities, and it is likely that our patients 
with severe JIA were less exposed to injuries than healthy children. Fractures 
were uncommon also in the study by Valta et al. (2007), where only 6% of 
patients with JIA had a history of peripheral fractures. Since these patients 
were evaluated at a relatively young age (median 12.4 years), they may not 
have reached the pubertal peak in fracture incidence. A more reliable estimate 
of the total risk for childhood fractures in patients with JIA can be derived 
only from studies extending to young adulthood, with careful assessment of 
physical activity and trauma mechanisms.  
Vertebral fractures are rare in healthy children, and except for those resulting 
from high-energy trauma, they are regarded as pathological fractures. 
Compression fractures may remain undetected, however, as they often are 
asymptomatic (Mäkitie et al. 2005, Valta et al. 2007, Nakhla et al. 2009, Rodd et al. 
2012). Compression fractures appear in several paediatric disease states, such as 
haematological or oncological conditions, solid organ or stem cell transplantation, 
neurolomuscular disabilities and conditions with chronic systemic inflammation 
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such as inflammatory bowel disease and rheumatic diseases (Helenius et al. 
2006, Kilpinen-Loisa et al. 2010, Laakso et al. 2012, Mäkitie et al. 2005, Taskinen 
et al. 2007, Valta et al. 2008 and 2009). In JIA, vertebral fractures have been 
detected, especially in systemic arthritis, but also in other JIA subtypes (Mäkitie 
et al. 2005, Valta et al. 2007, Nakhla et al. 2009, Huber et al. 2010). The vertebral 
fracture prevalence in our study, ranging from 22% to 28% depending on the 
cohort (refering to exclusion of those with poor thoracolumbar visibility on 
radiography) and imaging method, is the highest reported. This is probably due 
to the severe disease course in our selected patient population. Therefore, these 
results cannot be generalized to the overall JIA population. Furthermore, since 
most of our patients had been diagnosed before the era of biological drugs, 
which tend to be most effective in early disease, their disease course is likely 
to differ from that of patients diagnosed nowadays with similar disease. Our 
findings do, however, indicate the overall high risk for skeletal complications 
even during childhood in patients with JIA.
In our study, DXA-derived BMD was not a reliable indicator of bone health, 
as those with vertebral fractures had similar BMD Z-scores for LS and WB as 
those without fractures. Also others have observed a poor association between 
BMD and fractures (Goulding et al. 2000, Mäkitie et al. 2005, Valta et al. 2007, 
Nakhla et al. 2009). Mäyränpää et al. (2012) evaluated a cohort of otherwise 
healthy, but "fracture-prone" children, defined by their fracture history of 
two long bone fractures before the age of 10 years, three long bone fractures 
before the age of 16 years or one or more vertebral fractures at any age. 
These fracture-prone children had lower BMD values than healthy controls. 
In those with vertebral fractures, the mean lumbar spine BMD Z-score was 
also lower than in those without fractures but still within the normal range 
(-0.8), and whole-body BMD Z-score was even closer to zero (-0.3). Therefore, 
not only BMD, as determined by DXA, but also other characteristics of bone 
quality and strength seem to be important for fracture risk. Our study was 
cross-sectional and could not evaluate causal relationships, but our results 
support the idea that DXA alone is not an accurate method to assess fracture 
risk in children with JIA. At the fracture site, BMD may even be increased, and 
therefore, compressed vertebrae must be excluded from analyses. According to 
the current recommendations, DXA results should be corrected for body size 
(Crabtree et al. 2013). However, how these recommendations apply to children 
and adolescents with a chronic illness is unknown. Since many of our patients 
had abnormal bone age, and further, because compression fractures reduce 
height we decided to correct BMD results for bone age. However, it cannot be 
excluded that hand arthritis may have caused local advancement of growth and 
subsequently underestimation of BMD Z-scores in some patients. Concerning 
the severe disease course and high prevalence of compression fractures in our 
patients, even without correction for height, their DXA results were actually 
surprisingly good, again indicating that DXA has a limited value in evaluating 
bone health in this patient group. 
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Patients with compression fractures had higher cumulative three-year 
weight-adjusted GC dose than those without vertebral fractures, similar to 
earlier studies (Nakhla et al. 2009, Rodd et al. 2012). Multiple intra-articular 
GC injections may also have caused systemic effects in those with chronically 
active polyarthritis. Despite similar GC exposure, vertebral fractures have been 
less severe in patients with nephrotic syndrome than in those with paediatric 
rheumatic diseases  (Rodd et al. 2012, Phan et al. 2014), emphasizing the 
deleterious effects of inflammatory cytokines on bone (Schett et al. 2010a,b). 
Correspondingly, in our study, patients with compression fractures had higher 
parameters of current disease activity than patients without fractures. Because 
GCs are used more frequently in those with active disease and because GCs tend 
to increase fat mass, it is difficult to conclude whether high GC dose, disease 
activity and BMI are independent risk factors. In logistic regression analysis, the 
most significant associations with compression fractures were observed with 
CHAQ and BMI Z-score. Since CHAQ measures functional disability, those with 
compression fractures are likely to be the ones with the most severe disease 
course. Further, our findings are in line with recent observations suggesting 
that obesity is not beneficial for bone health. 
On spinal MRI, 28% of patients had vertebral fractures, which was more than 
seen by spinal radiography. Visibility on radiographs may be suboptimal, 
especially in the thoracic area and in obese persons, and MRI is able to show 
more detailed information about these changes (Sledge et al. 2001). This was 
observed also in our study. Similar to earlier observations, fractures occurred 
most often in the thoracic spine (Nakhla et al. 2009, Huber et al. 2010, Rodd 
et al. 2012). Patients with vertebral fractures on MRI tended to be more obese 
and to have higher cumulative weight-adjusted GC dose than those without 
fractures, but these differences were not statistically significant. No difference 
in disease activity parameters was observed between patients with and without 
fractures, in contrast to findings on radiography. There are various explanations 
for this discrepancy. Some patients were deemed to have vertebral fracture on 
radiographical analysis, but vertebral morphology did not fulfil the criteria for 
a compression fracture on MRI, and other patients’ fractures could only be 
detected on MRI. The rather small size of our study group and the non-normal 
distribution with a large variability of disease activity parameters may also 
account for these differences.   
6.2 Vitamin D and calcium
Somewhat surprisingly, those with compression fractures had reported higher 
daily intakes of vitamin D than those without fractures. This may reflect 
special attention to vitamin D intake in those with the most severe disease 
and high GC exposure. We observed a wide variation in reported daily 
intakes of calcium and vitamin D from diet and supplements, and some of 
the patients had received over three times more calcium and vitamin D daily 
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than recommended for healthy children at the time of the study. However, 
the evaluation of diet was limited since only 68% of patients completed the 
dietary recall, and it is possible that the reported dietary intakes of calcium and 
vitamin D are overestimated. Despite these high reported intakes, serum/plasma 
concentrations of calcium, phosphate and PTH were mainly normal. None of 
the patients had hypercalcaemia, and five patients had mild hypercalciuria. 
However, supranormal calcium intakes should be avoided and calcium 
preferably obtained from the diet, not only because it is more effective, but 
also because supplement use may be associated with increased cardiovascular 
risk and other adverse effects (Reid 2014). 
Considering the high reported vitamin D intakes, rather high 25-OHD serum 
concentrations were expected, but vitamin D status was suboptimal (<50 
nmol/l) in 38% (insufficient in 24% and deficient in 14%) of patients, and only 
one patient had a value over 80 nmol/l. High adiposity may contribute to these 
findings, possibly resulting from a reduced release of vitamin D stored in body 
fat (Misra and Klibanski 2013). However, our findings are in accordance with 
observations from the years 2007 to 2010 for 1351 Finnish children with chronic 
diseases, showing suboptimal 25-OHD values in 47% and deficiency (<37.5 
nmol/l) in 29% and 11% during the winter and summer months, respectively 
(Holmlund-Suila et al. 2013). Especially adolescents show low values. Vitamin D 
requirements may be higher in chronically ill children than in healthy children, 
resulting from alterations in absorption and metabolism of vitamin D. There 
has been controversy and active debate on the optimal serum 25-OHD level and 
on the recommended daily intake and the extraskeletal effects of vitamin D. 
In 2011, two different recommendations were published. Similar to the earlier 
recommendation (Misra et al. 2008), the Institute of Medicine suggests that a 
25-OHD concentration of >50 nmol/l is optimal for childhood growth and bone 
mass accrual (Ross et al. 2011). The Endocrine Society, in turn, recommends a 
higher concentration  (>75 nmol/l) based on potential long-term health benefits 
(Holick et al. 2011). According to several studies, vitamin D insufficiency and 
deficiency are common among children and adolescents in Finland (Lehtonen-
Veromaa et al. 2002, Pekkinen et al. 2012), and positive effects on bone mass 
accrual can be achieved with supplementation (Viljakainen et al. 2006). The 
Finnish National Nutrition Council Recommendations from 2014 have now 
increased the preferred daily intake of vitamin D for children and adolescents 
to 10 µg daily, which may not, however, be sufficient for all children (Pekkinen 
et al. 2012). Especially in children with a chronic disease and an increased risk for 
suboptimal bone health, higher intakes are probably needed. Obese subjects 
or those with malabsorption or medications affecting vitamin D metabolism, 
such as GCs, may need doses two to three times higher (Holick et al. 2011). It 
may thus be advisable to monitor serum 25-OHD concentration to optimize 
supplement requirements according to the serum concentrations attained. 
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6.3 Bone turnover markers
Earlier studies on bone turnover markers in JIA have reported mostly decreased 
levels of bone formation markers, often associated with active disease. 
More inconsistent results have been reported regarding resorption markers 
(Pepmueller et al. 1996, Lien et al. 2005). Contrary to our expectations, 
concentrations of bone formation markers did not differ between patients 
with severe JIA and healthy controls. However, the resorption marker ICTP was 
increased in patients, suggesting an imbalance in bone turnover. Since bone 
formation and resorption are tightly coupled, it is possible that increased bone 
resorption in patients leads to increased bone formation, and consequently, 
higher bone formation marker production. Since bone turnover markers 
reflect bone metabolism only over the short term, normal formation marker 
values may be related to relatively low current disease activity. Bone marker 
values did not correlate with disease activity in our patients, but studies on 
adults with RA have shown increased ICTP levels in association with disease 
activity and radiographic progression (Paimela et al. 1994). This marker reflects 
pathological matrix metalloproteinase-mediated bone resorption (Garnero et 
al. 2003), indicating that patients with severe disease do have pathological 
bone resorption.
6.4 Other findings on spinal magnetic resonance imaging
 
On MRI, we observed a variety of changes, including endplate irregularities 
(26%), anterior corner lesions (14%) and disc changes (46%) such as disc 
protrusion or prolapse (18%). The prevalence of these changes in our patients 
seemed high relative to the limited data in healthy paediatric populations, 
which mainly focus on the lumbar spine. Tertti et al. (1991) report lumbar disc 
degeneration in 26% of healthy 15-year-olds and in 38% of those with low 
back pain. Correspondingly, another study reports lumbar disc degeneration in 
one-third of 13-year-old children (Kjaer et al. 2005). Only 6% of these healthy 
children showed endplate changes, but a Finnish study observed endplate 
injury with disc degeneration in half of the children with previous traumatic 
vertebral wedge fractures (Kerttula et al. 2000). Probably resulting from 
recurrent trauma, male elite gymnasts in their thirties show a high prevalence 
(75%) of disc degeneration and a tendency for several other abnormalities of 
the thoracolumbar spine, e.g. Schmorl’s nodes, apophyseal ring abnormalities 
and abnormal configuration of the vertebral body (Swärd et al. 1991). Endplate 
injuries predispose to compromised nutrition and loss of integrity of the avascular 
intervertebral disc, and thereby, to disc degeneration and possibly to disrupted 
growth and development of the adjacent vertebrae (Hilton et al. 1976, Swärd 
et al. 1991). The adolescent spine has growth cartilage areas and immature 
ossification centres that are susceptible to injury (d’Hemecourt et al. 2000). An 
area of relative weakness exists at the osteocartilagineous junction, especially 
before complete fusion of the ring apophysis with the vertebral body (Keller 
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1974, Swärd et al. 1991). The exact aetiology and significance of the anterior 
corner defects that we detected remain, however, unknown. Three of our 
patients with severe compression fractures had disc ballooning, but normative 
MRI data on the prevalence of ballooning are lacking. Lumbar radiographs 
have shown disc ballooning in 15% of healthy Japanese adolescents (Tsuji et 
al. 1984). In our patients, obesity was associated with endplate irregularities, 
but tended to also be related to other changes on MRI. In adults, obesity is 
associated with low back pain and disc degeneration, suggested to result from 
either increased mechanical loads or other mechanisms such as adipokines and 
inflammatory cytokines (Samartzis et al. 2013). 
6.5 Body composition 
Body composition has not been systematically evaluated in JIA. Earlier studies 
have reported a tendency for malnutrition (Lofthouse et al. 2002, Bechtold and 
Roth 2009). In systemic arthritis, the basal energy expenditure is increased (Knops 
et al. 1999), but protein catabolism, induced by cytokines, exposes also other 
subgroups to malnutrition. Although GCs tend to promote fat accumulation and 
weight gain, they also cause muscle wasting. In earlier DXA studies, systemic 
GC exposure was related to increased fat mass (Mul et al. 2002, Lien et al. 2005, 
Caetano et al. 2012) and decreased lean mass (Mul et al. 2002, Lien et al. 2005). 
Recent studies report increased BMI or adiposity in JIA (Caetano et al. 2012, 
Pelajo et al. 2012, Grönlund et al. 2014). Obesity in our patients with severe JIA 
cannot be explained only by the global obesity epidemic since patients were 
clearly more obese than healthy controls. Potential contributing factors to the 
high fat mass include GC exposure and limited physical activity, but possible 
effects related to biological drugs cannot be excluded. Some adult studies have 
observed weight gain during anti-TNF therapy, and it is not known whether 
these drugs influence appetite or metabolism (Briot et al. 2008). However, the 
lean mass of our patients did not differ from that of controls. These unexpectedly 
normal values may at least partly result from a compensatory increase of lean 
mass with respect to high fat mass, but also methodological aspects may have a 
contributing role. 
High adiposity is associated with an increased risk for cardiovascular diseases 
(Matsson et al. 2008). Obesity may be especially harmful in rheumatic diseases, 
which per se predispose to cardiovascular complications. In paediatric rheumatic 
diseases, cardiovascular issues are of concern, especially in juvenile systemic lupus 
erythematosus. However, signs of a clinically silent atherosclerotic process have 
been found post-mortem also in patients with JIA (Smith et al. 2013). Obese 
children with JIA show elevated systolic blood pressure, dyslipidaemia, insulin 
resistance and subclinical cardiovascular changes such as increased intima-media 
thickness and left ventricle mass (Glowinska-Olszewska et al. 2013). Therefore, 
attempts to avoid overweight and obesity in JIA and other chronic inflammatory 
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diseases should be encouraged to prevent cardiovascular complications. 
Although malnutrition seems not to generally be a major problem, it may 
affect a small subgroup of children. In addition to the disease itself, adverse 
effects of medication, such as methotrexate, sulfasalazine or non-steroidal anti-
inflammatory drugs, may cause gastrointestinal symptoms and poor appetite. 
Despite the lack of data concerning the effects of nutritional supplementation 
on JIA, nutritional counselling and supplementation should be considered. 
Given that increasing obesity is a worldwide phenomenon also in the healthy 
paediatric population, results from our GC-treated Cohort with mostly relatively 
low-dose GC exposure (in those with current GC, mean daily dose was 2.9 mg or 
0.08 mg/kg) but normal growth, BMI and body composition are encouraging, 
highlighting the importance of rigorous disease control. Low GC dosages and 
an alternate-day regimen probably contribute to these favourable findings 
(Hochberg 2002), although no threshold for safe GC dosing is known. The slight 
decrease of bone mass may not necessarily have a clinically relevant impact 
on peak bone mass. Nevertheless, even though the cumulative GC exposure 
did not correlate with bone mass, an inverse correlation between the current 
weight-adjusted GC dose and BMD was observed. These findings emphasize 
the importance of avoiding systemic GC use, which nowadays is possible due to 
modern treatment modalities. 
6.6 Relationship between adipose tissue and bone 
Several observations in animal studies and clinical studies suggest a connection 
between adipose tissue and bone, which may be mediated partly via adipokines. 
In our study, patients with severe JIA had not only increased fat mass but also 
significantly higher serum leptin concentration, even independently of fat 
mass. In controls, the association between leptin and bone turnover markers 
attenuated when adjusted for fat mass, while in patients the association 
became stronger. Results were not significant when fully adjusted, possibly 
because of the rather small sample size, but were clearly different between 
patients and controls. These findings may be linked to a higher degree of 
obesity-related leptin resistance in patients, but also to leptin production 
at sites other than adipose tissue, even in joint tissues (Scotece et al. 2014). 
Further, our results imply that through other mechanisms in addition to 
increased fat mass leptin may contribute to suppression of bone turnover in 
JIA. Similar to studies in healthy children, no association between adiponectin 
and bone turnover markers emerged (Dimitri et al. 2011, Flemming et al. 2012). 
Because other studies have not evaluated the relationship between adipokines 
and bone turnover markers in JIA or other paediatric rheumatic diseases, these 
preliminary data offer a basis for further research.
The relationship between adipokines and bone mass was primarily evaluated 
in the GC-treated Cohort in comparison with controls. No association between 
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leptin and BMD was observed in either group. However, in the Severe JIA Cohort, 
an inverse association emerged, implying that leptin may have a negative 
effect on bone mass accrual in severe disease. This finding is also in line with 
the aforementioned tendency for an inverse association between leptin and 
bone turnover markers. Results from other studies on healthy lean or obese 
children regarding the relationship between leptin and bone mass are variable 
(Roemmich et al. 2003, Afghani and Goran 2009, Hong et al. 2010, Russell et al. 
2010). More consistent results have been reported regarding the relationship 
between adiponectin and bone mass since, similar to adults, observations show 
either an inverse association or no association (Hong et al. 2010, Russell et al. 
2010, Sayers et al. 2010). Consistent with this, we noted an inverse association 
between adiponectin and whole-body BMD in healthy controls, while in the 
GC-treated Cohort the association appeared only after correcting for bone 
age instead of pubertal stage. In those with severe JIA, no association existed. 
Disease- and treatment-related factors may have affected the results. 
6.7 Relationship between adipose tissue and disease activity 
Some studies report an association between obesity and disease activity or poor 
treatment response in adults with RA (Ajeganova et al. 2013, Sandberg et al. 
2014). Adipokines are suggested to play a role in immunity and inflammatory 
reactions in rheumatic diseases. Increased serum concentrations of leptin and 
adiponectin have been detected in adults with RA, often in association with 
increased disease activity (Gomez et al. 2011). Data are lacking regarding these 
issues in JIA. We did not observe a correlation between leptin or adiponectin 
and disease activity in patients with JIA, but this observation is limited because 
of low disease activity, especially in the GC-treated Cohort. However, studies 
in adults suggest that these adipokines may be contributing factors to or 
markers of pathogenesis and disease activity in rheumatic diseases and are 
even considered as possible drug targets (Scotece et al. 2014). Further studies 
on these and other adipokines in children with JIA are therefore warranted. 
6.8 Limitations of the study
Some limitations in our studies, related to either patient cohorts or applied 
methodologies, are noteworthy.
1) Study cohorts: The cross-sectional study design does not allow evaluation 
of causality, an issue for future research. The rather small study populations 
may have limited us from observing some significant findings and differences 
between the groups, did not allow comparison of girls and boys at different stages 
of pubertal maturation and caused limitations in correcting for confounding 
factors. As the Severe JIA Cohort represented a selected population, the results 
are not generalizable to the whole JIA population. However, we evaluated 
compression fractures, which are more likely to appear in severe disease, and 
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our results provide valuable data for the evaluation of bone health in patients 
with a severe disease course. 
2) Methodological aspects: DXA may have overestimated fat mass in the Severe 
JIA Cohort with high adiposity since increasing tissue depth and variation in fat 
distribution interfere with measurement and result in greater bias (Williams 
et al. 2006).  Other factors, including age, sex, body size and disease state, 
may have also caused bias in DXA body composition analysis. We were unable 
to differentiate between visceral and subcutaneous fat; recent data suggest 
that effects from visceral and subcutaneous fat deposits on bone may be the 
opposite (Gilsanz 2009); this warrants evaluation in future studies.  The exact 
amount and intensity of physical activity could not be compared between 
patients and controls. 
6.9 Future considerations
Despite advancements in medical therapy of JIA, compromised bone health 
remains a significant concern, especially in children with active and treatment-
resistant disease. Clinicians need to be aware of potential severe skeletal 
complications, including compression fractures. Guidelines are needed for 
assessment of bone health in clinical settings. According to a recent suggestion, 
paediatric patients with high risk for vertebral fractures should be screened 
annually with thoracolumbar radiography (LeBlanc et al. 2015). Despite 
limitations, DXA remains the most widely used technique to assess bone mass 
in clinical practice due to its good availability, low radiation dose and low 
cost. Modern DXA devices also allow vertebral fracture assessment, but its 
use is limited in children due to compromised visibility and poor diagnostic 
accuracy (Mäyränpää et al. 2007). However, peripheral computed tomography 
and other modern techniques enable the evaluation of bone geometry and 
bone strength, which are more accurate than DXA in detecting the mechanical 
competence of bone against fractures (Griffith et al. 2010). Guidelines are 
needed for effective treatment, including use of bisphosphonates, in secondary 
osteoporosis. Optimal vitamin D status and characterization of the role of 
vitamin D in rheumatic diseases are topics for future research. 
More accurate methods for body composition analysis in children are needed, 
especially for children with low or high fat content. To avoid misinterpretations, 
the terminology should be unambiguous. Longitudinal studies on body 
composition in JIA would be valuable. Longitudinal studies are also needed 
to evaluate the mechanisms and determinants of the fat-bone relationship 
through puberty and into adulthood, both in healthy children and in children 
with chronic disease. The role of brown adipose tissue is interesting because 
of suggested anabolic effects for bone (Ponrartana et al. 2012). Leptin and 
adiponectin affect bone metabolism through several mechanisms, but 
because of conflicting results their exact roles need to be elucidated. The role 
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of adipokines in JIA and other paediatric rheumatic diseases also warrants 
further studies. In addition to leptin and adiponectin, other adipokines, such 
as resistin and visfatin, are interesting candidates because these proteins have 
been suggested to have a role in the pathogenesis of RA (Scotece et al. 2014). 
Similarly, the possible contributing role of obesity and adipokines in vertebral 
changes should be investigated, as should the prevalence of these changes in 
the paediatric population and their significance in further morbidity.
As bones and body composition are constantly prone to changes while 
adapting to current requirements, the maintenance of a healthy life-style, 
optimal nutrition and continued physical activity should be encouraged in 
growing children and adolescents in order that they attain maximal peak bone 
mass and keep bones as strong as possible also in later life. These should also 
be targets for patients with JIA; adequate information and encouragement 
and individually tailored exercise programmes should be provided to prevent 
metabolic and cardiovascular complications and to ensure overall mental and 
physical well-being. 
DISCUSSION
77
7. CONCLUSIONS 
Several important conclusions can be drawn:
1. Patients with severe JIA have a high prevalence of vertebral fractures, 
indicating significantly compromised bone health. As vertebral fractures are 
often asymptomatic, screening with thoracolumbar radiography should be 
considered for patients with significant risk factors such as high GC exposure, 
sustained elevated disease activity and possibly obesity.
2. BMD measured with DXA does not reliably separate patients with and 
without compression fractures. 
3. MRI is suitable for detection of compression fractures. MRI also provides 
information about vertebral endplates and intervertebral discs, which are often 
affected in patients with severe JIA; high BMI may be one of the predisposing 
factors.
4. Opposite to healthy controls, leptin tended to be associated inversely with 
bone turnover markers in patients with severe JIA, suggesting that it may be a 
contributing factor for or a marker of decreased bone turnover in JIA. 
5. Patients with severe JIA have increased serum ICTP, suggesting pathologically 
increased bone resorption and imbalanced bone turnover.
6. Patients with severe JIA are prone to develop obesity. By contrast, in patients 
with less severe disease course, medication will usually ensure low disease 
activity and maintenance of normal BMI and body composition, despite GC 
exposure. 
7. Body composition does not differ between patients with low and normal 
lumbar spine BMD, when corrected for bone age. 
8. Leptin is not associated with BMD in children with JIA, although an inverse 
association may exist in those with severe disease, suggesting that leptin 
contributes to bone health in severe JIA. 
9. Serum leptin or adiponectin concentrations are not related to disease activity 
in patients with JIA. 
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